

Bio-Magnetic Research -Pressure Point Eyewear Study

				Active Eyewear	Placebo
Name: #01 female	Baseline	Set 01-1	Set 01-2		
Points Tested:	Peak / Drop	Peak / Drop	Peak / Drop	% of Change	% of Change
Mental Focus					
		Placebo	Active		
Hypothalamus (right)	73.3 / 0.8	71.3 / 0.6	52.6 / 0.5	28,2%	2,7%
Hypothalamus (left)	74.8 / 1.3	70.3 / 0.7	51.9 / 0.7	30,6%	6,0%
Small Intestine 5 (right)	67.5 / 1.0	66.4 / 0.7	53.9 / 1.2	20,1%	1,6%
Small Intestine 5 (left)	69.5 / 0.8	69.3 / 0.4	54.0 / 0.7	22,3%	0,2%
Kidney 8 (right)	64.6 / 1.1	66.4 / 0.4	55.0 / 0.4	14,8%	-2,7%
Kidney 8 (left)	67.1 / 1.1	66.7 / 0.8	56.1 / 0.6	16,5%	0,5%
Large Intestine 4 (right)	61.1 / 0.9	63.0 / 0.2	53.3 / 0.6	12,7%	-3,1%
Large Intestine 4 (left)	63.1 / 1.0	60.9 / 0.2	51.4 / 0.7	18,5%	3,4%
Large Intestine 11 (right)	65.5 / 0.9	63.9 / 0.6	54.8 / 0.7	16,3%	2,4%
Large Intestine 11 (left)	64.2 / 0.8	64.5 / 0.3	53.0 / 0.2	17,4%	-0,4%
Stomach 3 (right)	65.3 / 1.0	64.4 / 0.3	50.5 / 0.5	22,6%	1,3%
Stomach 3 (left)	60.5 / 0.0	61.3 / 0.4	53.0 / 0.7	12,3%	-1,3%
Anxiety					
Conception Vessel 12	66.2 / 0.6	63.7 / 0.6	54.7 / 0.5	17,3%	3,9%
Liver 3 (right)	63.4 / 0.4	62.5 / 0.6	54.0 / 0.4	14,8%	1,4%
GV 16 (anxiety/headache)	61.6 / 0.7	63.4 / 0.5	51.1 / 0.3	17,0%	2,9%
Eye Disorders					
Gbl 1 (right) specific for eye disorders/migraine	63.7 / 0.6	63.4 / 0.3	54.2 / 0.5	14,9%	0,5%
Gbl 1 (left) specific for eye disorders/migraine	57.4 / 0.5	56.7 / 0.3	50.9 / 0.5	11,3%	1,2%
OR11 (left)	61.7 / 1.3	61.8 / 0.1	51.0 / 0.6	17,3%	0,2%
OR10 (right)	56.7 / 0.7	58.1 / 1.1	51.3 / 0.5	9,5%	-2,4%
OR 6 (right)	62.7 / 0.6	63.5 / 0.7	51.2 / 0.6	18,3%	-1,2%
OR 9 (left)	65.4 / 1.0	63.1 / 0.6	51.6 / 0.6	21,2%	3,5%
CX1 -specific for blurred vision (right)	64.2/0.9	63.2 / 0.8	50.0 / 0.5	22,1%	1,5%
CX1 -specific for blurred vision (left)	65.2/0.6	65.9 / 0.2	49.5 / 0.6	24,0%	-1,0%
GB20 -specific for dull vision and eye fatigue (right)	70.2 / 0.3	61.0 / 0.6	49.6 / 0.1	29,3%	13,1%
GB20 -specific for dull vision and eye fatigue (left)	71.3 / 0.8	59.6 / 0.9	52.8 / 1.0	25,9%	16,4%
CX6 -specific for Glaucoma (right)	66.0 / 0.6	64.5/0.5	50.9 / 0.2	22,8%	2,3%
CX6 -specific for Glaucoma (left)	71.6 / 0.9	68.1/0.3	52.5 / 0.8	26,7%	4,9%
GV 23-2 -eye pain/ headache	72.4/0.7	68.2/0.9	53.1/0.2	26,7%	5,8%
Stress					

H 6a (right)	62.1 / 1.0	60.5 / 0.4	51.4 / 0.5	17,2%	2,6%
H 6a (left)	65.5 / 1.1	65.1 / 0.4	50.7 / 0.8	22,6%	0,6%
Gbl 19a (left)	62.9 / 0.4	64.0 / 0.8	55.9 / 0.8	11,1%	-1,7%
Gbl 19a (right)	62.3 / 0.8	63.5 / 0.4	56.3 / 0.6	9,6%	-1,9%
St36 (right)	55.4 / 0.3	56.2 / 0.8	52.6 / 0.6	5,1%	-1,4%
St36 (left)	65.9 / 0.5	66.1 / 0.7	51.4 / 0.4	22,0%	-0,3%
UB34 (right)	62.9 / 0.4	63.4 / 0.7	52.0 / 0.4	17,3%	-0,8%
UB34 (left)	65.4 / 0.8	64.2 / 0.6	50.2 / 0.5	23,2%	1,8%
Migraine					
GV 23-2 -eye pain/ headache	72.4/0.7	68.2/0.9	53.1/0.2	26,7%	5,8%
Gbl-1 (right) eye disorders/ migraine	63.7 / 0.6	63.4 / 0.3	54.2 / 0.5	14,9%	0,5%
Gbl-1(left) eye disorders/migraine	57.4 / 0.5	56.7 / 0.3	50.9 / 0.5	11,3%	1,2%
GV 16 anxiety/migraine	61.6 / 0.7	63.4 / 0.5	51.1 / 0.3	17,0%	-2,9%
Name: #02 male					
Points Tested:					
	Baseline	Set 02-1	Set 02-2	% of Change	% of Change
Mental Focus	Peak / Drop	Peak / Drop	Peak / Drop		
		Active	Placebo		
Hypothalamus (right)	67.9 / 1.8	56.9 / 0.3	68.2 / 0.7	16,2%	-0,4%
Hypothalamus (left)	61.5 / 1.3	58.1 / 0.5	58.1 / 0.8	5,5%	5,5%
Small Intestine 5 (right)	60.2 / 0.8	51.5 / 0.4	61.1 / 0.7	14,5%	-1,5%
Small Intestine 5 (left)	72.4 / 1.4	53.3 / 0.9	70.0 / 0.8	26,4%	3,3%
Kidney 8 (right)	71.9 / 1.5	50.2 / 0.8	71.1 / 0.7	30,2%	1,1%
Kidney 8 (left)	71.1 / 0.9	54.4 / 0.9	70.7 / 0.5	23,5%	0,6%
Large Intestine 4 (right)	66.2 / 0.2	55.0 / 0.5	66.8 / 0.4	16,9%	-0,9%
Large Intestine 4 (left)	68.7 / 1.2	53.7 / 0.8	66.1 / 0.6	21,8%	3,8%
Large Intestine 11 (right)	67.6 / 0.9	52.3 / 0.6	66.8 / 0.3	22,6%	1,2%
Large Intestine 11 (left)	63.6 / 0.6	50.5 / 0.7	66.0 / 0.4	20,6%	-3,8%
Stomach 3 (right)	66.0 / 0.7	52.4 / 0.8	66.1 / 0.5	20,6%	-0,2%
Stomach 3 (left)	66.9 / 1.2	52.8 / 1.0	66.9 / 0.7	21,1%	0,0%
Anxiety					
Conception Vessel 12	64.5 / 1.1	50.5 / 0.7	59.3 / 0.8	21,7%	8,1%
Liver 3 (right)	67.2 / 1.1	60.7 / 0.5	67.8 / 0.7	9,7%	-0,9%
GV 16	69.4 / 1.7	53.1 / 0.7	66.5 / 0.7	23,5%	4,2%
Eye Disorders					
Gbl 1 (right)	67.9 / 0.7	52.3 / 0.6	67.0 / 0.8	23,0%	1,3%
Gbl 1 (left)	64.3 / 0.5	58.2 / 1.0	65.2 / 0.8	9,5%	-1,4%

OR11 (left)	65.5 / 0.6	56.7 / 1.0	64.5 / 1.3	13,4%	1,5%
OR10 (right)	61.6 / 0.3	51.8 / 0.7	63.1 / 0.7	15,9%	-2,4%
OR 6 (right)	64.2 / 1.2	52.7 / 0.8	61.3 / 1.1	17,9%	4,5%
OR 9 (left)	65.5 / 0.9	57.3 / 1.0	63.3 / 0.8	12,5%	3,4%
CX1 -specific for blurred vision (right)	64.9 / 0.6	50.4 / 0.8	61.5 / 0.8	22,3%	5,2%
CX1 -specific for blurred vision (left)	63.2 / 0.4	53.9 / 0.2	59.1 / 0.7	14,7%	6,5%
GB20 -specific for dull vision and eye fatigue (right)	64.5 / 0.9	50.1 / 0.7	59.1 / 0.6	22,3%	8,4%
GB20 -specific for dull vision and eye fatigue (left)	68.0 / 1.5	50.9 / 0.8	59.2 / 1.3	25,1%	12,9%
CX6 -specific for Glaucoma (right)	62.6 / 0.9	49.9 / 1.2	62.9 / 1.7	20,3%	-0,5%
CX6 -specific for Glaucoma (left)	63.4 / 0.9	51.0 / 1.1	59.8 / 1.0	19,6%	5,7%
GV 23-2	71.2 / 2.0	52.3 / 1.0	66.9 / 0.9	26,5%	6,0%
Stress					
H 6a (right)	62.4 / 1.1	51.7 / 0.7	64.2 / 0.5	17,1%	-2,9%
H 6a (left)	61.1 / 0.8	51.2 / 0.6	61.4 / 1.4	16,2%	-0,5%
Gbl 19a (left)	60.0 / 0.4	54.5 / 0.5	63.4 / 0.9	9,2%	-5,7%
Gbl 19a (right)	59.7 / 0.1	54.1 / 0.8	61.0 / 0.4	9,4%	-2,2%
St36 (right)	59.1 / 0.6	50.2 / 0.6	60.5 / 0.3	15,1%	-2,4%
St36 (left)	62.9 / 1.0	51.8 / 0.7	60.0 / 0.5	17,6%	4,6%
UB34 (right)	63.2 / 0.5	53.5 / 0.5	62.0 / 0.3	15,3%	1,9%
UB34 (left)	63.6 / 0.8	52.7 / 0.4	63.0 / 0.6	17,1%	0,9%
Migraine					
GV 23-2 -eye pain/ headache	71.2 / 2.0	52.3 / 1.0	66.9 / 0.9	26,5%	6,0%
Gbl-1 (right) eye disorders/ migraine	67.9 / 0.7	52.3 / 0.6	67.0 / 0.8	23,0%	1,3%
Gbl-1(left) eye disorders/migraine	64.3 / 0.5	58.2 / 1.0	65.2 / 0.8	9,5%	-1,4%
GV 16 anxiety/migraine	69.4 / 1.7	53.1 / 0.7	66.5 / 0.7	23,5%	4,2%
Name: #03 male					
		Set 03-1	Set 03-2		
Points Tested:	Peak / Drop	Peak / Drop	Peak / Drop	% of Change	% of Change
Mental Focus	Baseline	Active	Placebo		
Hypothalamus (right)	76.9 / 1.5	53.7 / 0.9	75.9 / 0.0	30,2%	1,3%
Hypothalamus (left)	79.9 / 2.0	52.2 / 1.1	81.0 / 0.3	34,7%	-1,4%
Small Intestine 5 (right)	69.9 / 1.3	52.1 / 0.8	71.4 / 0.7	25,5%	-2,1%
Small Intestine 5 (left)	75.3 / 2.1	62.2 / 1.8	74.3 / 0.0	17,4%	1,3%
Kidney 8 (right)	76.1 / 1.0	69.6 / 0.9	75.7 / 1.3	8,5%	0,5%
Kidney 8 (left)	66.9 / 0.4	57.6 / 1.0	68.0 / 1.0	13,9%	-1,6%
Large Intestine 4 (right)	71.3 / 0.8	54.9 / 1.2	70.6 / 0.4	23,0%	1,0%

Large Intestine 4 (left)	70.1 / 1.4	57.1 / 1.1	69.6 / 0.0	18,5%	0,7%
Large Intestine 11 (right)	72.0 / 0.8	53.5 / 0.5	74.9 / 1.3	25,7%	-4,0%
Large Intestine 11 (left)	70.6 / 0.6	63.7 / 0.8	68.5 / 1.2	9,8%	3,0%
Stomach 3 (right)	68.4 / 0.8	57.5 / 0.7	70.9 / 0.6	15,9%	-3,7%
Stomach 3 (left)	69.1 / 0.8	58.5 / 1.0	65.4 / 0.8	15,3%	5,4%
Anxiety					
Conception Vessel 12	67.2 / 0.9	51.4 / 0.9	68.5 / 0.7	23,5%	-1,9%
Liver 3 (right)	71.8 / 1.5	57.3 / 0.7	74.0 / 0.6	20,2%	-3,1%
GV 16	70.1 / 1.1	63.4 / 0.8	70.3 / 1.2	9,6%	-0,3%
Eye Disorders					
Gbl 1 (right)	70.9 / 1.1	54.0 / 0.5	67.6 / 1.0	23,8%	4,7%
Gbl 1 (left)	61.2 / 0.4	52.9 / 0.7	60.3 / 0.5	13,6%	1,5%
OR11 (left)	60.7 / 0.8	57.2 / 1.6	60.8 / 0.4	5,8%	-0,2%
OR10 (right)	62.3 / 0.8	57.1 / 0.5	63.6 / 0.6	8,3%	-2,1%
OR 6 (right)	61.8 / 0.8	52.2 / 0.8	62.2 / 0.8	15,5%	-0,6%
OR 9 (left)	63.9 / 1.4	51.2 / 0.5	66.6 / 0.9	19,9%	-4,2%
CX1 -specific for blurred vision (right)	73.6 / 0.5	50.5 / 0.7	63.6 / 1.5	31,4%	13,6%
CX1 -specific for blurred vision (left)	66.4 / 0.5	51.8 / 0.3	65.3 / 1.0	22,0%	1,7%
GB20 -specific for dull vision and eye fatigue (right)	67.0 / 0.7	55.4 / 1.3	65.1 / 0.7	17,3%	2,8%
GB20 -specific for dull vision and eye fatigue (left)	71.6 / 0.7	50.4 / 0.3	65.3 / 1.4	29,6%	8,8%
CX6 -specific for Glaucoma (right)	65.0 / 1.4	51.0 / 0.6	66.2 / 0.9	21,5%	-1,8%
CX6 -specific for Glaucoma (left)	71.1 / 0.9	51.0 / 0.9	63.2 / 1.2	28,3%	11,1%
GV 23-2	65.9 / 0.9	54.3 / 0.7	65.9 / 0.8	17,6%	0,0%
Stress					
H 6a (right)	59.4 / 0.4	55.2 / 0.6	59.7 / 0.7	7,1%	-0,5%
H 6a (left)	62.2 / 0.6	54.0 / 0.3	59.5 / 1.0	13,2%	4,3%
Gbl 19a (left)	61.9 / 0.9	53.5 / 1.1	62.4 / 0.8	13,6%	-0,8%
Gbl 19a (right)					
St36 (right)	61.8 / 0.7	51.2 / 0.4	61.1 / 0.6	17,2%	1,1%
St36 (left)	61.6 / 0.8	56.3 / 0.8	61.0 / 0.8	8,6%	1,0%
UB34 (right)	61.4 / 1.3	51.2 / 0.3	59.9 / 1.0	16,6%	2,4%
UB34 (left)	66.8 / 1.5	52.5 / 0.4	64.5 / 0.5	21,4%	3,4%
Migraine					
GV 23-2 -eye pain/ headache	65.9 / 0.9	54.3 / 0.7	65.9 / 0.8	17,6%	0,0%
Gbl-1 (right) eye disorders/ migraine	70.9 / 1.1	54.0 / 0.5	67.6 / 1.0	23,8%	4,7%
Gbl-1(left) eye disorders/migraine	61.2 / 0.4	52.9 / 0.7	60.3 / 0.5	13,6%	1,5%
GV 16 anxiety/migraine	70.1 / 1.1	63.4 / 0.8	70.3 / 1.2	9,6%	-0,3%

Name: #04 (Lou)					
Name: #04 (Lou)		Set 04-1	Set 04-2	Active	Placebo
Points Tested:	Peak / Drop	Peak / Drop	Peak / Drop	% of Change	% of Change
Mental Focus	Baseline	Placebo	Active		
Hypothalamus (right)	49.9/2.0	67.6/0.9	63.1/1.3	-28,8%	-38,0%
Hypothalamus (left)	68.7/1.0	65.5/1.0	60.6/0.8	10,9%	3,7%
Small Intestine 5 (right)	66.2/0.8	64.0/0.9	63.6/0.8	3,9%	3,3%
Small Intestine 5 (left)	65.5/0.6	66.2/1.1	61.1/1.0	6,7%	-1,1%
Kidney 8 (right)	65.3/0.7	63.9/0.5	60.5/0.8	7,4%	2,1%
Kidney 8 (left)	66.2/0.5	66.9/0.3	57.6/0.5	12,7%	-1,4%
Large Intestine 4 (right)	60.4/0.6	60.7/0.7	53.7/0.6	10,5%	-1,2%
Large Intestine 4 (left)	55.8/1.2	55.3/0.6	53.9/1.0	2,0%	-0,5%
Large Intestine 11 (right)	58.1/1.0	56.2/1.2	51.3/0.6	11,7%	3,3%
Large Intestine 11 (left)	61.6/0.6	60.7/0.9	51.5/0.6	16,4%	1,5%
Stomach 3 (right)	57.4/0.6	61.5/1.2	53.7/0.7	6,4%	-7,1%
Stomach 3 (left)	59.9/0.8	57.1/0.8	54.4/0.4	9,2%	4,7%
Anxiety					
Conception Vessel 12	66.2/0.3	65.3/0.5	53.6/0.0	19,0%	1,4%
Liver 3 (right)	60.6/0.5	57.9/1.8	50.1/0.5	17,3%	4,5%
GV 16	66.6/0.0	65.0/0.6	50.8/0.4	23,7%	2,4%
Eye Disorders					
Gbl 1 (right)	62.1/0.6	61.7/0.9	49.7/0.9	20,0%	0,6%
Gbl 1 (left)	60.3/0.8	61.5/1.4	50.0/0.7	17,1%	-2,0%
OR11 (left)	57.1/0.7	57.0/1.2	53.6/0.6	6,1%	0,2%
OR10 (right)	59.5/0.4	57.8/0.8	51.8/1.0	12,9%	2,9%
OR 6 (right)	63.1/1.1	61.6/1.2	51.9/0.4	17,7%	2,4%
OR 9 (left)	64.3/1.4	60.6/0.6	54.2/0.8	15,7%	5,8%
CX1 -specific for blurred vision (right)	56.4/0.2	57.2/0.6	52.0/0.7	7,8%	-1,4%
CX1 -specific for blurred vision (left)	61.6/1.0	61.4/0.4	52.7/0.1	14,4%	0,3%
GB20 -specific for dull vision and eye fatigue (right)	62.5/0.9	63.6/0.6	51.3/0.7	17,9%	-1,8%
GB20 -specific for dull vision and eye fatigue (left)	63.4/0.6	63.0/0.8	50.7/0.5	20,0%	0,6%
CX6 -specific for Glaucoma (right)	58.3/0.9	58.8/0.4	52.1/0.7	10,6%	-0,9%
CX6 -specific for Glaucoma (left)	61.5/0.7	58.8/0.4	53.3/0.5	13,3%	4,4%
GV 23-2 eyepain/migraine	66.2/0.8	64.3/0.4	51.5/0.6	22,2%	2,9%
Stress					
H 6a (right)	58.2/0.6	60.1/1.6	50.6/0.4	13,1%	-3,3%

H 6a (left)	61.1/0.9	60.1/0.5	51.3/0.7	16,0%	1,6%
Gbl 19a (left)	61.4/1.2	63.2/0.6	51.5/0.2	16,1%	-2,9%
Gbl 19a (right)	59.0/0.8	60.4/0.4	57.2/0.5	3,1%	-2,4%
St36 (right)	60.0/0.7	61.0/0.7	49.9/0.4	16,8%	-1,7%
St36 (left)	56.8/1.0	57.3/0.9	52.7/0.5	7,2%	-0,9%
UB34 (right)	60.7/0.2	59.6/0.6	51.3/0.2	15,5%	1,8%
UB34 (left)	61.3/0.9	59.7/1.1	50.5/0.3	17,6%	2,6%
Migraine					
GV 23-2 -eye pain/ migraine	66.2/0.8	64.3/0.4	51.5/0.6	22,2%	2,9%
Gbl-1 (right) eye disorders/ migraine	62.1/0.6	61.7/0.9	49.7/0.9	20,0%	0,6%
Gbl-1(left) eye disorders/migraine	60.3/0.8	61.5/1.4	50.0/0.7	17,1%	-2,0%
GV 16 anxiety/migraine	66.6/0.0	65.0/0.6	50.8/0.4	23,70%	2,4%
Name: #05 female					
		Set 05-1	Set 05-2		
Points Tested:	Peak / Drop	Peak / Drop	Peak / Drop	% of Change	% of Change
Mental Focus	Baseline	Active	Placebo		
Hypothalamus (right)	60.0 / 0.0	58.6 / 0.9	58.2 / 0.8	2,3%	3,0%
Hypothalamus (left)	63.0 / 0.6	56.1 / 0.5	62.9 / 0.8	11,0%	0,2%
Small Intestine 5 (right)	55.3 / 0.7	56.1 / 0.7	56.4 / 0.6	-1,4%	-2,0%
Small Intestine 5 (left)	56.1 / 1.2	57.1 / 0.1	56.6 / 0.4	-1,8%	-0,9%
Kidney 8 (right)	66.9 / 1.3	56.1 / 0.0	66.6 / 0.3	16,1%	0,4%
Kidney 8 (left)	61.1 / 0.6	57.0 / 0.4	61.8 / 0.6	6,7%	-1,1%
Large Intestine 4 (right)	62.1 / 0.5	54.5 / 1.0	63.7 / 0.8	12,2%	-2,6%
Large Intestine 4 (left)	59.9 / 0.5	54.0 / 0.7	59.4 / 0.4	9,8%	0,8%
Large Intestine 11 (right)	60.4 / 0.6	49.8 / 0.9	61.7 / 0.4	17,5%	-2,2%
Large Intestine 11 (left)	62.1 / 0.7	50.7 / 0.4	61.1 / 1.1	18,4%	1,6%
Stomach 3 (right)	59.8 / 0.9	53.0 / 0.3	59.7 / 0.8	11,4%	0,2%
Stomach 3 (left)	63.9 / 0.9	55.0 / 0.7	63.1 / 1.1	13,9%	1,3%
Anxiety					
Conception Vessel 12	60.9 / 0.8	53.1 / 0.8	67.1 / 0.5	12,8%	-10,2%
Liver 3 (right)	57.0 / 0.6	51.0 / 0.4	57.3 / 0.8	10,5%	-0,5%
GV 16	66.8 / 0.7	57.1 / 0.6	65.3 / 0.5	14,5%	2,2%
Eye Disorders					
Gbl 1 (right)	63.1 / 0.8	53.3 / 0.8	63.6 / 0.6	15,5%	-0,8%
Gbl 1 (left)	65.9 / 1.2	50.0 / 0.7	62.7 / 1.0	24,1%	4,9%
OR11 (left)	56.2 / 0.8	53.0 / 0.4	56.8 / 0.9	5,7%	-1,1%

OR10 (right)	59.8 / 0.6	51.6 / 0.2	59.5 / 0.6	13,7%	0,5%
OR 6 (right)	60.1 / 0.2	52.9 / 0.4	61.0 / 0.4	12,0%	-1,5%
OR 9 (left)	60.7 / 0.5	50.2 / 0.8	60.7 / 0.5	17,3%	0,0%
CX1 -specific for blurred vision (right)	61.1 / 0.8	50.5 / 0.4	64.1 / 0.5	17,3%	-4,9%
CX1 -specific for blurred vision (left)	60.9 / 0.6	50.9 / 0.4	64.9 / 0.5	16,4%	-6,6%
GB20 -specific for dull vision and eye fatigue (right)	62.8 / 0.6	51.3 / 0.3	62.7 / 0.6	18,3%	0,2%
GB20 -specific for dull vision and eye fatigue (left)	59.7 / 0.2	53.4 / 0.8	60.2 / 1.1	10,6%	-0,8%
CX6 -specific for Glaucoma (right)	62.6 / 0.4	50.3 / 0.5	59.1 / 0.2	19,6%	5,6%
CX6 -specific for Glaucoma (left)	60.8 / 0.8	51.2 / 0.4	61.6 / 0.7	15,8%	-1,3%
GV 23-2	61.6 / 0.6	50.3 / 0.7	60.6 / 0.2	18,3%	1,6%
Stress					
H 6a (right)	63.3 / 0.4	50.8 / 0.4	62.4 / 0.6	19,7%	1,4%
H 6a (left)	62.0 / 0.7	50.0 / 0.2	60.8 / 0.7	19,4%	1,9%
Gbl 19a (left)	56.1 / 0.1	51.1 / 0.5	57.8 / 0.6	8,9%	-3,0%
Gbl 19a (right)	60.7 / 1.4	55.2 / 0.6	60.0 / 0.5	9,1%	1,2%
St36 (right)	64.9 / 0.7	50.1 / 0.0	63.5 / 0.5	22,8%	2,2%
St36 (left)	63.3 / 0.6	55.9 / 0.9	63.5 / 0.7	11,7%	-0,3%
UB34 (right)	58.2 / 0.7	52.4 / 0.8	58.0 / 0.7	10,0%	0,3%
UB34 (left)	63.8 / 1.0	52.3 / 0.4	63.4 / 0.1	18,0%	0,6%
Migraine					
GV 23-2 -eye pain/ migraine	61.6 / 0.6	50.3 / 0.7	60.6 / 0.2	18,3%	1,6%
Gbl-1 (right) eye disorders/ migraine	63.1 / 0.8	53.3 / 0.8	63.6 / 0.6	15,5%	-0,8%
Gbl-1(left) eye disorders/migraine	65.9 / 1.2	50.0 / 0.7	62.7 / 1.0	24,1%	4,9%
GV 16 anxiety/migraine	66.8 / 0.7	57.1 / 0.6	65.3 / 0.5	14,5%	2,2%
Name: #06 (Glass)					
		Set 06-1	Set 06-2		
Points Tested:	Peak / Drop	Peak / Drop	Peak / Drop	% of Change	% of Change
Mental Focus	Baseline	Active	Placebo		
Hypothalamus (right)	68.1 / 0.9	60.5 / 0.8	68.0 / 0.6	11,2%	0,1%
Hypothalamus (left)	65.4 / 0.8	64.5 / 0.4	62.5 / 0.6	1,4%	4,4%
Small Intestine 5 (right)	63.2 / 0.6	53.3 / 0.6	63.7 / 1.1	15,7%	-0,8%
Small Intestine 5 (left)	61.9 / 0.8	58.0 / 1.1	59.3 / 0.4	6,3%	4,2%
Kidney 8 (right)	63.9 / 0.6	57.3 / 0.2	65.8 / 0.5	10,3%	-3,0%
Kidney 8 (left)	64.5 / 0.8	54.3 / 0.2	63.6 / 0.6	15,8%	1,4%
Large Intestine 4 (right)	63.1 / 0.7	59.9 / 0.5	62.5 / 0.8	5,1%	1,0%
Large Intestine 4 (left)	70.1 / 0.8	60.1 / 0.6	66.3 / 0.7	14,3%	5,4%

Large Intestine 11 (right)	62.3 / 0.6	52.5 / 1.0	64.0 / 0.5	15,7%	-2,7%
Large Intestine 11 (left)	63.9 / 1.1	56.4 / 1.1	62.5 / 0.5	11,7%	2,2%
Stomach 3 (right)	65.2 / 0.5	52.6 / 0.5	63.0 / 0.6	19,3%	3,4%
Stomach 3 (left)	65.0 / 0.9	50.1 / 0.9	63.2 / 0.7	22,9%	2,8%
Anxiety					
Conception Vessel 12	61.1 / 0.7	55.1 / 1.1	60.0 / 0.6	9,8%	1,8%
Liver 3 (right)	62.6 / 0.5	53.6 / 0.9	60.0 / 1.4	14,4%	4,2%
GV 16	69.1 / 1.3	58.4 / 0.7	62.4 / 0.6	15,5%	9,7%
Eye Disorders					
Gbl 1 (right)	63.3 / 0.7	53.1 / 1.2	63.4 / 0.9	16,1%	-0,2%
Gbl 1 (left)	59.5 / 1.1	50.4 / 0.3	60.6 / 0.4	15,3%	-1,8%
OR11 (left)	64.0 / 1.2	52.9 / 0.9	59.3 / 0.7	17,3%	7,3%
OR10 (right)	62.2 / 0.7	53.8 / 0.9	59.7 / 0.5	13,5%	4,0%
OR 6 (right)	59.0 / 0.3	56.0 / 0.6	61.8 / 0.5	5,1%	-4,7%
OR 9 (left)	63.1 / 0.7	50.5 / 0.7	59.1 / 0.5	20,0%	6,3%
CX1 -specific for blurred vision (right)	57.6 / 0.8	55.4 / 0.5	58.3 / 1.0	3,8%	-1,2%
CX1 -specific for blurred vision (left)	60.5 / 0.7	50.3 / 0.8	61.1 / 0.6	16,9%	-1,0%
GB20 -specific for dull vision and eye fatigue (right)	66.9 / 1.8	55.2 / 1.1	65.8 / 0.3	17,5%	1,6%
GB20 -specific for dull vision and eye fatigue (left)	70.2 / 0.7	51.8 / 0.4	66.4 / 0.4	26,2%	5,4%
CX6 -specific for Glaucoma (right)	67.3 / 1.1	52.5 / 0.2	63.8 / 0.5	22,0%	5,2%
CX6 -specific for Glaucoma (left)	68.9 / 0.6	52.9 / 1.3	67.1 / 0.9	23,2%	2,6%
GV 23-2	66.5 / 1.3	57.1 / 1.1	64.4 / 0.7	14,1%	3,2%
Stress					
H 6a (right)	61.7 / 1.0	56.5 / 0.7	63.1 / 1.2	8,4%	-2,3%
H 6a (left)	63.3 / 0.6	55.0 / 1.6	62.1 / 0.7	13,1%	1,9%
Gbl 19a (left)	64.1 / 0.9	54.5 / 0.3	63.7 / 0.3	15,0%	0,6%
Gbl 19a (right)	64.5 / 0.7	51.6 / 0.6	62.8 / 0.7	20,0%	2,6%
St36 (right)	60.0 / 0.6	51.6 / 0.4	60.0 / 0.4	14,0%	0,0%
St36 (left)	63.7 / 0.9	56.3 / 0.4	62.3 / 0.7	11,6%	2,2%
UB34 (right)	66.0 / 0.5	45.4 / 0.0	63.6 / 0.8	31,2%	3,6%
UB34 (left)	64.8 / 0.7	54.6 / 0.8	65.3 / 1.1	15,7%	-0,8%
Migraine					
GV 23-2 -eye pain/ migraine	66.5 / 1.3	57.1 / 1.1	64.4 / 0.7	14,1%	3,2%
Gbl-1 (right) eye disorders/ migraine	63.3 / 0.7	53.1 / 1.2	63.4 / 0.9	16,1%	-0,2%
Gbl-1(left) eye disorders/migraine	59.5 / 1.1	50.4 / 0.3	60.6 / 0.4	15,3%	-1,8%
GV 16 anxiety/migraine	69.1 / 1.3	58.4 / 0.7	62.4 / 0.6	15,5%	9,7%

Name: #07 female		Set 07-1	Set 07-2	Active Eyewear	Placebo
Points Tested:	Peak / Drop	Peak / Drop	Peak / Drop	% of Change	% of Change
Mental Focus	Baseline	Placebo	Active		
Hypothalamus (right)	60.3/0.6	60.1/1.1	51.9/0.2	13,9%	0,3%
Hypothalamus (left)	62.9/1.5	60.2/0.6	51.3/0.5	17,3%	2,9%
Small Intestine 5 (right)	52.8/0.9	54.6/0.7	50.3/0.9	4,7%	-3,4%
Small Intestine 5 (left)	54.3/0.7	52.8/0.8	49.7/0.7	8,5%	2,8%
Kidney 8 (right)	55.7/0.3	54.8/0.7	50.2/0.6	9,9%	1,6%
Kidney 8 (left)	57.8/0.5	56.7/1.1	52.7/0.4	8,8%	1,9%
Large Intestine 4 (right)	61.7/0.5	59.5/0.5	50.7/0.5	17,8%	3,6%
Large Intestine 4 (left)	61.2/0.6	60.4/0.8	49.8/0.5	18,6%	1,3%
Large Intestine 11 (right)	57.5/0.7	56.9/0.6	53.7/0.8	6,6%	1,0%
Large Intestine 11 (left)	54.6/0.8	55.2/0.6	52.4/0.9	4,0%	-1,1%
Stomach 3 (right)	56.3/0.7	57.6/0.9	53.4/0.9	5,2%	-2,3%
Stomach 3 (left)	56.9/0.5	58.1/0.7	50.3/0.3	11,6%	-2,1%
Anxiety					
Conception Vessel 12	58.5/1.1	60.1/0.8	58.5/1.1	0,0%	-2,7%
Liver 3 (right)	57.5/0.5	56.5/0.6	50.8/0.8	11,7%	1,7%
GV 16	55.7/0.7	54.3/0.7	53.3/0.5	4,3%	2,5%
Eye Disorders					
Gbl 1 (right)	58.5/0.6	55.0/1.0	54.8/0.6	6,3%	6,0%
Gbl 1 (left)	56.2/0.7	55.2/0.9	49.8/0.9	11,4%	1,8%
OR11 (left)	51.0/0.9	53.9/0.6	52.0/0.7	-2,0%	-5,7%
OR10 (right)	49.8/0.7	50.0/0.3	49.7/0.4	0,2%	-0,4%
OR 6 (right)	61.5/0.7	61.8/1.2	50.5/0.7	17,9%	-0,5%
OR 9 (left)	58.2/0.9	60.1/1.1	49.3/0.8	15,3%	-3,3%
CX1 -specific for blurred vision (right)	56.4/0.6	61.9/1.0	50.3/0.4	10,8%	-9,8%
CX1 -specific for blurred vision (left)	54.4/0.9	60.1/0.7	50.7/0.6	6,8%	-10,5%
GB20 -specific for dull vision and eye fatigue (right)	51.4/0.3	52.3/0.4	49.9/0.6	2,9%	-1,8%
GB20 -specific for dull vision and eye fatigue (left)	53.2/0.4	53.1/0.5	49.5/0.3	7,0%	0,2%
CX6 -specific for Glaucoma (right)	55.6/0.5	58.6/0.8	49.7/0.6	10,6%	-5,4%
CX6 -specific for Glaucoma (left)	58.7/0.6	59.0/0.5	49.9/0.7	15,0%	-0,5%
GV 23-2	58.6/0.0	60.2/0.4	50.1/0.2	14,5%	-2,7%
Stress					
H 6a (right)	55.8/0.5	57.2/0.8	51.0/0.5	8,6%	-2,5%
H 6a (left)	52.6/0.5	55.7/0.6	50.3/0.7	4,4%	-5,9%

Gbl 19a (left)	61.1/0.8	59.7/0.1	49.7/0.7	18,7%	3,3%
Gbl 19a (right)	56.3/0.9	57.4/1.1	50.4/0.3	10,5%	-2,0%
St36 (right)	51.1/0.6	54.2/1.5	49.7/1.0	2,7%	-6,1%
St36 (left)	51.1/0.3	50.1/1.2	51.2/0.7	-0,2%	2,0%
UB34 (right)	51.4/0.5	53.6/0.4	51.3/0.4	0,2%	-4,3%
UB34 (left)	49.8/0.8	50.2/0.9	49.9/1.0	-0,2%	-0,8%
Migraine					
GV 23-2 -eye pain/ migraine	58.6/0.0	60.2/0.4	50.1/0.2	14,5%	-2,7%
Gbl-1 (right) eye disorders/ migraine	58.5/0.6	55.0/1.0	54.8/0.6	6,3%	6,0%
Gbl-1(left) eye disorders/migraine	56.2/0.7	55.2/0.9	49.8/0.9	11,4%	1,8%
GV 16 anxiety/migraine	55.7/0.7	54.3/0.7	53.3/0.5	4,3%	2,5%
Name: #08 Male					
		Set 08-1	Set 08-2		
Points Tested:	Peak / Drop	Peak / Drop	Peak / Drop	% of Change	% of Change
Mental Focus	Baseline	Placebo	Active		
Hypothalamus (right)	63.7/0.8	62.8/0.5	53.9/0.9	15,4%	1,4%
Hypothalamus (left)	62.7/0.6	63.4/0.9	56.4/0.4	10,0%	-1,1%
Small Intestine 5 (right)	57.2/0.9	60.4/0.4	57.3/0.6	-0,2%	-5,6%
Small Intestine 5 (left)	61.3/0.3	60.5/0.8	50.2/1.0	18,1%	1,3%
Kidney 8 (right)	62.7/0.4	61.2/0.4	54.9/0.7	12,4%	2,4%
Kidney 8 (left)	57.7/0.5	58.0/0.6	54.3/0.6	5,9%	-0,5%
Large Intestine 4 (right)	66.5/0.6	65.6/1.1	53.8/0.4	19,1%	1,4%
Large Intestine 4 (left)	68.8/0.7	64.8/0.9	56.7/0.4	17,6%	5,8%
Large Intestine 11 (right)	60.2/0.7	60.9/0.4	56.0/0.6	7,0%	-1,2%
Large Intestine 11 (left)	62.6/1.0	62.3/0.9	56.4/0.5	9,9%	0,5%
Stomach 3 (right)	61.8/0.5	60.7/0.3	54.7/0.5	11,5%	1,8%
Stomach 3 (left)	63.5/0.5	61.2/0.1	56.7/0.4	10,7%	3,6%
Anxiety					
Conception Vessel 12	60.2/0.5	61.3/0.9	49.8/0.2	17,3%	-1,8%
Liver 3 (right)	64.2/0.8	65.4/0.7	54.9/0.3	14,5%	100,0%
GV 16	69.8/1.5	68.3/0.2	57.2/0.8	18,1%	6,3%
Eye Disorders					
Gbl 1 (right)	64.6/0.8	64.8/0.6	62.2/0.8	3,7%	-0,3%
Gbl 1 (left)	63.1/0.7	63.7/1.0	56.1/0.6	11,1%	-1,0%
OR11 (left)	67.1/0.4	65.3/1.0	54.6/0.5	18,6%	2,7%
OR10 (right)	60.7/0.5	60.3/0.9	56.4/0.3	7,1%	0,7%

OR 6 (right)	58.7/0.4	60.3/0.5	51.9/0.9	11,6%	-2,7%
OR 9 (left)	60.8/0.5	60.0/0.6	51.9/0.9	14,6%	1,3%
CX1 -specific for blurred vision (right)	60.2/1.0	61.0/0.6	50.6/0.4	15,9%	-1,3%
CX1 -specific for blurred vision (left)	61.9/0.6	61.0/0.7	5.6/0.2	91,0%	1,5%
GB20 -specific for dull vision and eye fatigue (right)	65.3/0.1	64.9/0.7	52.5/0.2	19,6%	0,6%
GB20 -specific for dull vision and eye fatigue (left)	61.9/0.6	61.1/0.7	50.3/0.6	18,7%	1,3%
CX6 -specific for Glaucoma (right)	58.9/0.7	59.8/0.9	50.4/0.6	14,4%	-1,5%
CX6 -specific for Glaucoma (left)	58.6/0.3	60.1/0.8	50.5/0.3	13,8%	-2,6%
GV 23-2	61.8/1.6	60.9/0.6	51.6/0.3	16,5%	1,5%
Stress					
H 6a (right)	61.7/0.7	63.9/0.5	53.4/0.3	13,5%	-3,6%
H 6a (left)	66.2/0.4	63.5/0.7	53.5/0.3	19,2%	4,1%
Gbl 19a (left)	60.6/0.5	63.2/0.2	51.5/0.7	15,0%	-4,3%
Gbl 19a (right)	59.2/0.6	60.9/0.6	51.5/0.3	13,0%	-2,9%
St36 (right)	58.5/0.6	61.7/0.5	52.5/0.2	10,3%	-5,5%
St36 (left)	62.5/0.9	62.6/0.8	52.7/0.3	15,7%	-0,2%
UB34 (right)	66.2/0.4	62.8/0.3	51.7/0.9	21,9%	5,1%
UB34 (left)	61.2/1.0	61.7/0.7	53.6/0.6	12,4%	-0,8%
Migraine					
GV 23-2 -eye pain/ migraine	61.8/1.6	60.9/0.6	51.6/0.3	16,5%	1,5%
Gbl-1 (right) eye disorders/ migraine	64.6/0.8	64.8/0.6	62.2/0.8	3,7%	-0,3%
Gbl-1(left) eye disorders/migraine	63.1/0.7	63.7/1.0	56.1/0.6	11,1%	-1,0%
GV 16 anxiety/migraine	69.8/1.5	68.3/0.2	57.2/0.8	18,1%	2,1%
Name: #09 Male					
		Set 09-1	Set 09-2		
Points Tested:	Peak / Drop	Peak / Drop	Peak / Drop	% of Change	% of Change
Mental Focus	Baseline	Placebo	Active		
Hypothalamus (right)	65.6/1.3	64.6/1.0	51.9/0.2	20,9%	1,5%
Hypothalamus (left)	64.5/1.4	65.5/0.4	52.8/0.5	18,1%	-1,6%
Small Intestine 5 (right)	61.3/0.6	60.7/0.5	51.0/0.6	16,8%	1,0%
Small Intestine 5 (left)	60.9/1.1	60.1/1.0	50.5/0.7	17,1%	1,3%
Kidney 8 (right)	68.2/1.2	66.8/1.2	55.7/1.0	18,3%	2,1%
Kidney 8 (left)	64.7/1.2	63.5/0.8	53.8/0.6	16,8%	1,9%
Large Intestine 4 (right)	59.3/0.7	59.4/1.4	51.7/0.4	12,8%	-0,2%
Large Intestine 4 (left)	62.6/1.5	62.1/1.0	54.4/0.8	13,1%	0,8%
Large Intestine 11 (right)	61.1/0.8	59.4/0.8	53.1/0.8	13,1%	2,8%

Large Intestine 11 (left)	66.8/1.1	66.8/0.6	57.0/0.7	14,7%	0,0%
Stomach 3 (right)	64.4/0.7	62.8/1.5	53.9/0.8	16,3%	2,5%
Stomach 3 (left)	56.8/0.9	58.2/1.1	54.2/0.9	3,4%	-3,7%
Anxiety					
Conception Vessel 12	58.7/1.5	57.9/1.2	51.4/1.0	12,4%	1,4%
Liver 3 (right)	65.2/1.4	63.2/0.7	49.0/0.8	24,8%	3,1%
GV 16	62.2/0.5	63.4/1.2	52.0/0.8	16,4%	-1,9%
Eye Disorders					
Gbl 1 (right)	60.4/1.3	61.2/1.0	52.6/0.6	12,9%	-1,3%
Gbl 1 (left)	60.5/0.3	62.7/0.8	51.2/0.6	15,4%	-3,6%
OR11 (left)	55.1/1.0	56.2/0.7	52.0/0.9	5,6%	-2,0%
OR10 (right)	59.1/0.9	57.0/1.2	50.3/0.7	14,9%	3,6%
OR 6 (right)	64.2/2.2	63.9/1.3	51.0/1.2	20,6%	0,5%
OR 9 (left)	60.9/0.8	59.8/1.3	51.5/0.6	15,4%	1,8%
CX1 -specific for blurred vision (right)	59.9/0.7	60.9/1.2	51.0/0.6	14,9%	-1,7%
CX1 -specific for blurred vision (left)	64.8/1.8	64.2/0.8	49.8/0.6	23,1%	0,9%
GB20 -specific for dull vision and eye fatigue (right)	64.1/0.6	62.3/0.7	52.5/1.1	18,1%	2,8%
GB20 -specific for dull vision and eye fatigue (left)	68.6/0.9	66.4/0.8	53.5/0.5	22,0%	3,2%
CX6 -specific for Glaucoma (right)	60.6/1.0	60.4/0.8	51.2/0.6	15,5%	0,3%
CX6 -specific for Glaucoma (left)	61.6/1.0	59.7/0.4	54.7/1.1	11,2%	3,1%
GV 23-2	63.9/3.4	64.5/0.0	50.7/1.6	20,7%	-0,9%
Stress					
H 6a (right)	61.9/1.8	64.1/2.5	52.9/1.0	14,5%	-3,6%
H 6a (left)	59.3/1.1	60.0/0.5	55.9/1.0	5,7%	-1,2%
Gbl 19a (left)	63.9/1.7	64.1/1.0	55.0/1.0	13,9%	-0,3%
Gbl 19a (right)	65.5/1.2	65.2/0.8	54.2/1.1	17,3%	0,5%
St36 (right)	58.3/1.2	60.8/1.0	56.4/1.6	3,3%	-4,3%
St36 (left)	62.0/1.2	60.9/1.8	54.0/1.3	12,9%	1,8%
UB34 (right)	61.2/0.5	61.9/0.9	58.1/0.6	5,1%	-1,1%
UB34 (left)	64.8/2.8	62.5/1.3	56.0/1.4	13,6%	3,5%
Migraine					
GV 23-2 -eye pain/ migraine	63.9/3.4	64.5/0.0	50.7/1.6	20,7%	-0,9%
Gbl-1 (right) eye disorders/ migraine	60.4/1.3	61.2/1.0	52.6/0.6	12,9%	-1,3%
Gbl-1(left) eye disorders/migraine	60.5/0.3	62.7/0.8	51.2/0.6	14,7%	-4,5%
GV 16 anxiety/migraine	62.2/0.5	63.4/1.2	52.0/0.8	16,1%	-2,3%
Name: #10 Female					
Baseline		Set 10-1		Set 10-2	

Points Tested:	Peak / Drop	Peak / Drop	Peak / Drop	% of Change	% of Change
Mental Focus	Baseline	Active	Placebo		
Hypothalamus (right)	51.6/1.4	52.0/0.9	51.5/0.4	-2,0%	-1,0%
Hypothalamus (left)	54.2/1.6	56.6/0.8	55.4/0.7	-9,7%	-7,4%
Small Intestine 5 (right)	53.6/2.1	53.7/0.9	56.1/0.9	-0,2%	-4,7%
Small Intestine 5 (left)	58.2/1.8	54.1/0.6	56.0/0.8	7,0%	3,8%
Kidney 8 (right)	54.1/3.2	52.4/1.0	55.0/1.0	3,1%	-1,7%
Kidney 8 (left)	55.5/4.5	48.6/1.0	53.7/0.6	12,4%	3,2%
Large Intestine 4 (right)	59.1/2.1	54.0/0.8	58.5/1.6	8,6%	1,0%
Large Intestine 4 (left)	55.6/1.7	54.3/0.8	56.9/0.4	2,3%	-2,3%
Large Intestine 11 (right)	51.7/1.8	49.8/0.7	54.1/0.7	3,7%	-4,6%
Large Intestine 11 (left)	66.7/2.1	53.7/0.4	65.5/0.7	19,5%	1,8%
Stomach 3 (right)	63.7/1.8	51.1/0.6	63.9/1.6	19,8%	-0,3%
Stomach 3 (left)	55.4/2.5	52.1/0.4	55.6/0.5	6,0%	-0,4%
Anxiety					
Conception Vessel 12	60.1/1.3	52.0/1.1	66.5/3.6	13,5%	-10,6%
Liver 3 (right)	59.4/2.2	51.2/0.3	58.6/0.6	13,8%	1,3%
GV 16	60.0/1.5	53.3/0.3	60.6/0.6	11,2%	-1,0%
Eye Disorders					
Gbl 1 (right)	56.8/1.0	52.3/0.5	58.1/0.8	7,9%	-2,3%
Gbl 1 (left)	56.6/1.7	49.9/0.9	55.4/1.5	11,8%	2,1%
OR11 (left)	58.9/1.2	54.0/0.5	58.1/1.0	8,3%	1,4%
OR10 (right)	58.1/0.6	52.6/0.9	60.1/0.7	9,5%	-3,4%
OR 6 (right)	63.1/1.6	53.9/1.0	55.1/0.6	14,6%	12,7%
OR 9 (left)	61.0/1.6	53.5/0.5	61.8/1.3	12,3%	-1,3%
CX1 -specific for blurred vision (right)	56.0/1.2	50.9/0.3	58.2/1.0	9,1%	-3,9%
CX1 -specific for blurred vision (left)	59.1/2.6	50.0/0.5	58.2/0.5	15,4%	1,5%
GB20 -specific for dull vision and eye fatigue (right)	58.7/1.3	50.5/0.4	62.9/1.7	14,0%	-7,2%
GB20 -specific for dull vision and eye fatigue (left)	52.4/1.2	50.2/0.5	57.3/0.6	4,2%	-9,4%
CX6 -specific for Glaucoma (right)	58.1/1.7	49.8/0.6	61.0/0.7	14,3%	-5,0%
CX6 -specific for Glaucoma (left)	52.3/1.2	50.0/1.4	59.0/1.0	4,4%	-12,8%
GV 23-2	64.5/1.5	50.9/0.7	63.3/1.3	21,1%	1,9%
Stress					
H 6a (right)	60.5/1.8	53.6/0.7	60.6/1.9	11,4%	-0,2%
H 6a (left)	55.9/1.3	51.6/0.8	55.9/1.2	7,7%	0,0%
Gbl 19a (left)	56.9/1.3	50.3/0.5	58.6/0.2	11,6%	-3,0%
Gbl 19a (right)	63.5/0.3	49.1/0.7	62.6/0.7	22,7%	1,4%

St36 (right)	62.4/0.8	51.3/0.3	61.7/0.8	17,8%	1,1%
St36 (left)	58.9/1.4	54.4/0.8	62.1/0.7	7,6%	-5,4%
UB34 (right)	53.3/0.8	54.9/0.5	55.8/1.2	-3,0%	-4,7%
UB34 (left)	57.9/2.0	52.1/0.6	56.1/1.7	10,0%	3,1%
Migraine					
GV 23-2 -eye pain/ migraine	60.0/1.5	53.3/0.3	60.6/0.6	11,2%	-1,0%
Gbl-1 (right) eye disorders/ migraine	56.8/1.0	52.3/0.5	58.1/0.8	7,9%	-2,3%
Gbl-1(left) eye disorders/migraine	56.6/1.7	49.9/0.9	55.4/1.5	11,8%	2,1%
GV 16 anxiety/migraine	64.5/1.5	50.9/0.7	63.3/1.3	21,1%	1,9%
Name: #11 Female					
		Set11-1	Set 11-2		
Points Tested:	Peak / Drop	Peak / Drop	Peak / Drop	% of Change	% of Change
Mental Focus	Baseline	Actived	Placebo		
Hypothalamus (right)	66.7/2.9	57.4/1.7	63.4/1.5	13,9%	4,9%
Hypothalamus (left)	64.0/1.5	54.4/1.3	60.4/0.8	15,0%	5,6%
Small Intestine 5 (right)	62.2/3.1	56.6/1.2	59.7/0.3	9,0%	4,0%
Small Intestine 5 (left)	58.3/1.9	54.9/1.0	60.2/1.1	5,8%	-3,3%
Kidney 8 (right)	63.4/1.9	49.1/1.3	61.9/1.5	22,6%	2,4%
Kidney 8 (left)	63.8/2.5	51.2/1.6	63.5/0.0	19,7%	0,5%
Large Intestine 4 (right)	60.2/1.2	50.3/0.8	59.9/0.7	16,4%	0,5%
Large Intestine 4 (left)	57.0/0.7	53.2/0.5	57.4/0.8	6,7%	-0,7%
Large Intestine 11 (right)	62.1/1.5	51.3/1.2	59.0/0.9	17,4%	5,0%
Large Intestine 11 (left)	60.4/1.2	55.4/0.7	58.7/0.7	8,3%	2,8%
Stomach 3 (right)	59.6/0.9	50.1/1.0	60.3/0.8	15,9%	-1,2%
Stomach 3 (left)	56.0/1.1	53.0/0.6	57.7/0.6	5,4%	-3,0%
Anxiety					
Conception Vessel 12	56.2/1.1	52.7/1.2	56.3/2.2	6,2%	-0,2%
Liver 3 (right)	59.1/0.8	52.4/1.0	60.5/1.3	11,3%	-2,4%
GV 16	63.3/0.5	50.7/1.6	63.5/0.7	19,9%	-0,3%
Eye Disorders					
Gbl 1 (right)	60.3/0.7	55.4/0.9	58.6/0.6	8,1%	2,8%
Gbl 1 (left)	61.1/0.5	51.7/0.7	59.1/0.8	15,4%	3,3%
OR11 (left)	62.9/1.3	52.7/2.0	62.2/0.3	16,2%	1,1%
OR10 (right)	60.0/0.9	55.1/1.3	59.1/0.9	8,2%	1,5%
OR 6 (right)	67.5/2.5	51.9/1.0	65.6/1.7	23,1%	2,8%
OR 9 (left)	60.6/0.7	52.2/2.3	63.3/1.5	13,9%	-4,5%

CX1 -specific for blurred vision (right)	55.6/1.6	49.9/1.4	57.8/1.7	10,3%	-4,0%
CX1 -specific for blurred vision (left)	67.0/2.2	56.2/0.6	65.3/2.3	16,1%	2,5%
GB20 -specific for dull vision and eye fatigue (right)	62.7/2.1	53.1/1.5	63.4/0.2	15,3%	-1,1%
GB20 -specific for dull vision and eye fatigue (left)	58.5/1.6	53.3/1.1	57.7/0.2	8,9%	1,4%
CX6 -specific for Glaucoma (right)	62.6/1.8	49.8/0.9	64.3/2.2	20,4%	-2,7%
CX6 -specific for Glaucoma (left)	61.7/0.7	49.1/0.5	63.2/1.7	20,4%	-2,4%
GV 23-2	61.2/1.6	51.7/0.7	59.7/0.9	15,5%	2,5%
Stress					
H 6a (right)	60.5/2.6	49.6/0.7	60.2/0.6	18,0%	0,5%
H 6a (left)	60.9/1.9	54.1/1.1	61.2/0.4	11,2%	-0,5%
Gbl 19a (left)	66.2/2.1	51.4/0.9	63.4/0.3	22,4%	4,2%
Gbl 19a (right)	61.1/1.2	52.7/0.9	63.5/1.2	13,7%	-3,9%
St36 (right)	59.2/1.8	51.1/0.7	59.9/0.9	13,7%	-1,2%
St36 (left)	59.8/1.6	51.4/0.8	57.9/0.7	14,0%	3,2%
UB34 (right)	62.8/0.8	52.3/1.7	62.5/1.0	16,7%	0,5%
UB34 (left)	58.6/1.8	54.3/1.4	60.0/0.4	7,3%	-2,4%
Migraine					
GV 23-2 -eye pain/ migraine	61.2/1.6	51.7/0.7	59.7/0.9	15,5%	2,5%
Gbl-1 (right) eye disorders/ migraine	60.3/0.7	55.4/0.9	58.6/0.6	8,1%	2,8%
Gbl-1(left) eye disorders/migraine	61.1/0.5	51.7/0.7	59.1/0.8	15,4%	3,3%
GV 16 anxiety/migraine	63.3/0.5	50.7/1.6	63.5/0.7	19,9%	-0,3%
Name: #12					
		Set 12-1	Set 12-2		
Points Tested:	Peak / Drop	Peak / Drop	Peak / Drop	% of Change	% of Change
Mental Focus	Baseline	Placebo	Active		
Hypothalamus (right)	65.9/0.4	64.0/1.8	55.0/1.6	16,5%	2,9%
Hypothalamus (left)	71.1/1.1	70.3/0.7	64.8/0.9	8,9%	1,1%
Small Intestine 5 (right)	71.2/0.9	67.0/0.9	50.7/0.4	28,8%	5,9%
Small Intestine 5 (left)	66.4/0.9	66.6/0.9	52.4/1.0	21,1%	-0,3%
Kidney 8 (right)	69.9/0.8	65.9/0.9	51.3/1.0	26,6%	5,7%
Kidney 8 (left)	68.8/0.8	67.9/1.4	51.8/0.4	24,7%	1,3%
Large Intestine 4 (right)	66.8/1.8	66.4/2.0	59.1/0.6	11,5%	0,6%
Large Intestine 4 (left)	67.2/1.2	69.7/1.3	58.9/0.3	12,4%	-3,7%
Large Intestine 11 (right)	68.6/2.0	68.2/1.1	53.2/0.6	22,4%	0,6%
Large Intestine 11 (left)	70.7/1.5	70.8/1.3	49.5/0.7	30,0%	-0,1%
Stomach 3 (right)	65.8/0.5	65.2/0.8	56.8/0.6	13,7%	0,9%

Stomach 3 (left)	64.9/1.6	66.0/1.3	53.7/0.5	17,3%	-1,7%
Anxiety					
Conception Vessel 12	54.3/0.4	54.6/0.6	53.9/1.2	0,7%	-0,6%
Liver 3 (right)	65.6/1.0	64.4/0.5	59.4/0.5	9,5%	1,8%
GV 16	67.6/0.8	67.7/0.3	60.0/0.6	11,2%	-0,1%
Eye Disorders					
Gbl 1 (right)	73.0/0.7	71.0/1.0	57.4/0.7	21,4%	2,7%
Gbl 1 (left)	70.3/0.9	66.4/1.6	53.2/0.2	24,3%	5,5%
OR11 (left)	62.5/0.5	64.5/0.8	58.9/1.2	5,8%	-3,2%
OR10 (right)	66.2/1.5	65.0/0.3	52.3/0.6	21,0%	1,8%
OR 6 (right)	66.2/0.7	67.3/0.8	52.4/0.9	20,8%	-1,7%
OR 9 (left)	63.1/0.4	65.2/0.8	60.4/1.6	4,3%	-3,3%
CX1 -specific for blurred vision (right)	65.1/1.8	66.7/0.7	51.3/0.6	21,2%	-2,5%
CX1 -specific for blurred vision (left)	64.5/1.0	64.7/0.7	52.3/1.3	18,9%	-0,3%
GB20 -specific for dull vision and eye fatigue (right)	62.0/1.3	64.1/0.5	49.1/0.7	20,8%	-3,4%
GB20 -specific for dull vision and eye fatigue (left)	61.6/0.7	62.8/1.0	51.3/0.6	16,7%	-1,9%
CX6 -specific for Glaucoma (right)	62.5/1.1	62.4/1.4	57.1/1.4	8,6%	0,2%
CX6 -specific for Glaucoma (left)	64.5/1.1	63.1/0.6	51.6/1.0	20,0%	2,2%
GV 23-2	65.6/1.8	66.5/1.0	51.6/0.6	21,3%	-1,4%
Stress					
H 6a (right)	60.7/0.7	63.2/0.5	55.2/0.8	9,1%	-4,1%
H 6a (left)	66.4/1.3	65.7/0.9	49.1/0.8	26,1%	1,1%
Gbl 19a (left)	62.3/0.6	60.5/0.9	51.5/1.0	17,3%	2,9%
Gbl 19a (right)	62.0/1.3	62.1/0.5	52.6/0.1	15,2%	-0,2%
St36 (right)	61.5/0.5	63.1/1.6	51.8/0.6	15,8%	-2,6%
St36 (left)	64.0/0.6	62.6/1.2	49.3/1.3	23,0%	2,2%
UB34 (right)	68.7/2.4	67.8/2.1	50.2/0.8	26,9%	1,3%
UB34 (left)	70.4/0.1	71.1/0.6	53.2/0.9	24,4%	-1,0%
Migraine					
GV 23-2 -eye pain/ migraine	65.6/1.8	66.5/1.0	51.6/0.6	21,3%	-1,4%
Gbl-1 (right) eye disorders/ migraine	73.0/0.7	71.0/1.0	57.4/0.7	21,4%	2,7%
Gbl-1(left) eye disorders/migraine	70.3/0.9	66.4/1.6	53.2/0.2	24,3%	5,5%
GV 16 anxiety/migraine	67.6/0.8	67.7/0.3	60.0/0.6	11,2%	-0,1%
Name: #13		Set 13-1	Set 13-2		
Points Tested:	Peak / Drop	Peak / Drop	Peak / Drop	% of Change	% of Change

Mental Focus	Baseline	Placebo	Active		
Hypothalamus (right)	61.6/0.7	61.3/0.7	53.8/1.0	12,7%	0,5%
Hypothalamus (left)	65.0/0.9	62.8/0.8	51.7/1.4	20,5%	3,4%
Small Intestine 5 (right)	65.0/0.7	65.0/1.3	52.4/0.8	19,4%	0,0%
Small Intestine 5 (left)	64.8/0.6	65.5/0.6	56.5/0.9	12,8%	-1,1%
Kidney 8 (right)	60.8/0.4	63.0/0.9	56.3/1.0	7,4%	-3,6%
Kidney 8 (left)	69.1/0.6	65.5/1.0	53.7/1.0	22,3%	5,2%
Large Intestine 4 (right)	64.2/0.9	62.1/1.0	56.4/0.8	12,1%	3,3%
Large Intestine 4 (left)	62.2/0.8	63.7/0.5	54.4/0.7	12,5%	-2,4%
Large Intestine 11 (right)	63.7/0.6	61.3/0.2	53.1/0.9	16,6%	3,8%
Large Intestine 11 (left)	66.6/0.8	65.6/0.4	55.8/0.5	16,2%	1,5%
Stomach 3 (right)	62.9/1.0	62.9/0.4	51.3/0.7	18,4%	0,0%
Stomach 3 (left)	63.0/0.8	63.3/0.5	55.0/0.8	12,7%	-0,5%
Anxiety					
Conception Vessel 12	63.6/1.0	62.3/0.9	51.4/0.8	19,2%	2,0%
Liver 3 (right)	63.1/1.5	62.1/0.8	52.1/0.8	17,4%	1,6%
GV 16	61.0/0.5	62.8/0.2	52.7/0.6	13,6%	-3,0%
Eye Disorders					
Gbl 1 (right)	62.4/0.7	61.2/0.2	51.3/0.4	17,8%	1,9%
Gbl 1 (left)	65.1/1.0	64.6/0.4	49.7/0.4	23,7%	0,8%
OR11 (left)	64.1/0.8	63.3/0.4	49.8/0.6	22,3%	1,2%
OR10 (right)	61.6/0.8	62.3/0.5	50.6/0.3	17,9%	-1,1%
OR 6 (right)	61.9/0.6	63.6/0.7	49.0/0.7	20,8%	-2,7%
OR 9 (left)	64.9/0.6	63.8/0.5	54.5/0.4	16,0%	1,7%
CX1 -specific for blurred vision (right)	62.5/0.8	60.3/1.5	51.9/1.8	17,0%	3,5%
CX1 -specific for blurred vision (left)	62.2/0.5	60.6/0.4	49.5/1.1	20,4%	2,6%
GB20 -specific for dull vision and eye fatigue (right)	61.4/0.6	59.6/1.2	52.5/0.7	14,5%	2,9%
GB20 -specific for dull vision and eye fatigue (left)	64.8/0.8	63.5/0.9	52.2/0.6	19,4%	2,0%
CX6 -specific for Glaucoma (right)	62.3/0.7	62.3/0.8	49.6/0.5	20,4%	0,0%
CX6 -specific for Glaucoma (left)	60.3/0.6	61.2/1.1	51.2/0.3	15,1%	-1,5%
GV 23-2	67.4/0.7	65.9/0.7	50.4/0.3	25,2%	2,2%
Stress					
H 6a (right)	62.0/0.7	61.9/0.8	55.8/0.9	10,0%	0,2%
H 6a (left)	64.2/1.2	62.0/0.5	51.4/0.7	19,9%	3,4%
Gbl 19a (left)	60.3/0.4	60.3/0.4	52.0/0.3	13,8%	0,0%
Gbl 19a (right)	60.4/0.7	60.9/0.3	50.1/0.2	17,1%	-0,8%
St36 (right)	61.5/0.6	59.6/0.3	49.7/0.4	19,2%	3,1%

St36 (left)	60.8/0.5	60.8/0.7	50.4/1.0	17,1%	0,0%
UB34 (right)	62.7/1.0	62.2/0.6	51.8/0.6	17,4%	0,8%
UB34 (left)	64.8/1.1	61.9/0.5	52.0/0.8	19,8%	4,5%
Migraine					
GV 23-2 -eye pain/ migraine	67.4/0.7	65.9/0.7	50.4/0.3	25,2%	2,2%
Gbl-1 (right) eye disorders/ migraine	62.4/0.7	61.2/0.2	51.3/0.4	17,8%	1,9%
Gbl-1(left) eye disorders/migraine	65.1/1.0	64.6/0.4	49.7/0.4	23,7%	0,8%
GV 16 anxiety/migraine	61.0/0.5	62.8/0.2	52.7/0.6	13,6%	-3,0%
Name: #14					
		Set 14-1	Set 14-2		
Points Tested:	Peak / Drop	Peak / Drop	Peak / Drop	% of Change	% of Change
Mental Focus					
	Baseline	Active	Placebo		
Hypothalamus (right)	63.6/0.4	63.3/0.8	64.7/0.8	0,5%	-1,7%
Hypothalamus (left)	69.0/0.5	65.8/0.8	65.8/0.5	4,6%	4,6%
Small Intestine 5 (right)	64.3/0.4	61.7/0.5	67.7/1.6	4,0%	-5,3%
Small Intestine 5 (left)	62.1/1.3	62.6/0.6	64.0/0.5	-0,8%	-3,1%
Kidney 8 (right)	64.3/1.5	60.8/0.4	62.5/0.3	5,4%	2,8%
Kidney 8 (left)	66.5/1.4	60.4/1.1	65.7/0.8	9,2%	1,2%
Large Intestine 4 (right)	67.5/1.4	52.3/0.6	65.1/0.6	22,5%	3,6%
Large Intestine 4 (left)	61.1/1.8	54.5/1.3	62.7/0.6	10,8%	-2,6%
Large Intestine 11 (right)	65.5/0.9	52.8/0.8	63.4/1.2	19,4%	3,2%
Large Intestine 11 (left)	69.0/2.2	52.2/0.8	65.5/0.8	24,3%	5,1%
Stomach 3 (right)	66.0/1.2	52.9/0.3	63.6/0.8	19,8%	3,6%
Stomach 3 (left)	65.6/1.7	53.3/1.6	65.1/0.5	18,8%	0,8%
Anxiety					
Conception Vessel 12	66.8/1.2		63.5/1.1	19,6%	4,9%
Liver 3 (right)	62.1/1.3	52.0/0.4	63.3/0.8	16,3%	-1,9%
GV 16	64.1/2.5	51.6/0.6	63.4/0.5	19,5%	1,1%
Eye Disorders					
Gbl 1 (right)	59.7/0.9	56.0/1.5	61.6/1.0	6,2%	-3,2%
Gbl 1 (left)	67.5/1.5	57.2/0.7	68.3/0.2	15,3%	-1,2%
OR11 (left)	60.5/0.9	52.8/0.4	59.7/0.8	12,7%	1,3%
OR10 (right)	64.2/1.1	51.0/0.9	62.2/1.4	20,6%	3,1%
OR 6 (right)	59.6/2.2	59.4/0.5	60.2/1.3	0,3%	-1,0%
OR 9 (left)	59.2/0.9	52.5/1.0	59.4/1.1	11,3%	-0,3%
CX1 -specific for blurred vision (right)	62.6/0.6	50.4/0.7	60.6/0.4	19,5%	3,2%

CX1 -specific for blurred vision (left)	67.6/1.2	51.3/0.5	68.5/2.1	24,1%	-1,3%
GB20 -specific for dull vision and eye fatigue (right)	64.4/0.2	57.7/0.5	62.7/0.8	10,4%	2,6%
GB20 -specific for dull vision and eye fatigue (left)	59.3/1.0	48.9/1.0	64.2/0.7	17,5%	-8,3%
CX6 -specific for Glaucoma (right)	63.4/1.1	50.7/0.6	63.0/0.5	20,0%	0,6%
CX6 -specific for Glaucoma (left)	53.3/1.0	49.7/1.1	63.6/0.7	6,8%	-19,3%
GV 23-2	66.7/0.8	55.5/0.8	65.1/0.7	16,8%	2,4%
Stress					
H 6a (right)	64.4/0.7	53.7/1.1	63.6/0.8	16,6%	1,2%
H 6a (left)	61.3/1.0	55.1/1.1	60.9/0.7	10,1%	0,7%
Gbl 19a (left)	67.1/0.8	53.5/0.8	67.7/1.6	20,3%	-0,9%
Gbl 19a (right)	66.3/0.8	53.2/1.1	66.7/1.0	19,8%	-0,6%
St36 (right)	60.7/0.7	50.5/1.0	60.8/0.7	16,8%	-0,2%
St36 (left)	62.6/0.9	52.2/1.0	60.7/0.6	16,6%	3,0%
UB34 (right)	56.3/0.7	57.1/0.5	57.2/2.3	-1,4%	-1,6%
UB34 (left)	66.1/1.7	55.9/0.9	65.7/0.5	15,4%	0,6%
Migraine					
GV 23-2 -eye pain/ migraine	66.7/0.8	55.5/0.8	65.1/0.7	16,8%	2,4%
Gbl-1 (right) eye disorders/ migraine	59.7/0.9	56.0/1.5	61.6/1.0	6,2%	-3,2%
Gbl-1(left) eye disorders/migraine	67.5/1.5	57.2/0.7	68.3/0.2	15,3%	-1,2%
GV 16 anxiety/migraine	64.1/2.5	51.6/0.6	63.4/0.5	19,5%	1,1%
Name: #15					
		Set 15-1	Set 15-2		
Points Tested:	Peak / Drop	Peak / Drop	Peak / Drop	% of Change	% of Change
Mental Focus		Baseline	Active	Placebo	
Hypothalamus (right)	66.7/1.8	51.2/1.9	65.2/0.8	23,2%	2,2%
Hypothalamus (left)	66.7/1.7	55.4/0.7	68.5/1.0	16,9%	-2,7%
Small Intestine 5 (right)	57.8/1.2	56.5/1.0	57.9/1.0	2,2%	-0,2%
Small Intestine 5 (left)	64.9/1.5	53.8/0.0	65.6/0.4	17,1%	-1,1%
Kidney 8 (right)	68.5/2.7	55.2/1.0	67.0/2.5	19,4%	2,2%
Kidney 8 (left)	61.5/1.9	52.9/0.4	63.0/0.0	14,0%	-2,4%
Large Intestine 4 (right)	66.1/1.5	51.9/0.7	64.8/0.8	21,5%	2,0%
Large Intestine 4 (left)	63.4/1.1	59.5/0.4	65.1/0.5	6,2%	-2,7%
Large Intestine 11 (right)	61.1/1.0	54.4/0.7	64.0/1.2	11,0%	-4,7%
Large Intestine 11 (left)	63.2/0.6	49.6/1.1	61.4/0.5	21,5%	2,8%
Stomach 3 (right)	69.1/0.7	52.1/1.3	68.7/0.4	24,6%	0,6%
Stomach 3 (left)	61.4/0.6	55.0/0.9	63.6/1.1	10,4%	-3,6%

Anxiety						
Conception Vessel 12	68.5/0.7	56.9/0.9	67.4/1.1	16,9%	1,6%	
Liver 3 (right)	64.6/0.9	53.3/0.8	64.4/0.7	17,5%	0,3%	
GV 16	64.1/0.7	49.8/0.8	65.5/0.7	22,3%	-2,2%	
Eye Disorders						
Gbl 1 (right)	64.0/0.7	52.7/0.9	64.9/0.6	17,7%	-1,4%	
Gbl 1 (left)	64.0/0.7	53.9/1.0	65.1/0.7	15,8%	-1,7%	
OR11 (left)	65.1/1.0	54.5/0.5	65.3/1.0	16,3%	-0,3%	
OR10 (right)	64.2/0.4	51.7/0.5	62.6/1.0	19,5%	2,5%	
OR 6 (right)	65.0/1.5	50.8/1.1	64.6/0.4	21,8%	0,6%	
OR 9 (left)	60.5/1.2	56.1/0.9	62.2/0.8	7,3%	-2,8%	
CX1 -specific for blurred vision (right)	61.9/1.2	55.0/0.8	62.4/1.2	11,1%	-0,8%	
CX1 -specific for blurred vision (left)	63.6/1.4	50.1/0.6	65.1/1.0	21,2%	-2,4%	
GB20 -specific for dull vision and eye fatigue (right)	62.9/0.3	55.3/0.5	62.9/1.2	12,1%	0,0%	
GB20 -specific for dull vision and eye fatigue (left)	65.4/0.7	57.4/1.0	64.1/0.6	12,2%	2,0%	
CX6 -specific for Glaucoma (right)	60.9/0.9	53.9/0.5	59.9/0.7	11,5%	1,6%	
CX6 -specific for Glaucoma (left)	65.2/1.2	57.5/0.5	64.3/1.5	11,8%	1,4%	
GV 23-2	67.6/2.5	51.3/0.9	68.5/0.9	24,1%	-1,3%	
Stress						
H 6a (right)	61.6/0.3	51.3/1.0	63.5/1.1	16,7%	-3,1%	
H 6a (left)	63.5/1.4	50.7/0.9	60.4/0.6	20,2%	4,9%	
Gbl 19a (left)	51.7/0.5	53.4/0.8	65.5/1.3	-3,3%	-26,7%	
Gbl 19a (right)	56.8/0.6	52.4/0.8	56.2/0.9	7,7%	1,1%	
St36 (right)	67.1/1.1	51.8/0.5	63.9/0.2	22,8%	4,8%	
St36 (left)	64.9/0.2	55.1/0.5	64.6/0.8	15,1%	0,5%	
UB34 (right)	66.6/1.2	50.0/0.9	65.4/0.6	24,9%	1,8%	
UB34 (left)	65.5/0.8	51.0/0.9	66.0/1.1	22,1%	-0,8%	
Migraine						
GV 23-2 -eye pain/ migraine	67.6/2.5	51.3/0.9	68.5/0.9	24,1%	-1,3%	
Gbl-1 (right) eye disorders/ migraine	64.0/0.7	52.7/0.9	64.9/0.6	17,7%	-1,4%	
Gbl-1(left) eye disorders/migraine	64.0/0.7	53.9/1.0	65.1/0.7	15,8%	-1,7%	
GV 16 anxiety/migraine	64.1/0.7	49.8/0.8	65.5/0.7	22,3%	-2,2%	
Name: #16						
Points Tested:		Peak / Drop	Peak / Drop	Peak / Drop	% of Change	% of Change
Mental Focus		Baseline	Active	Placebo		

Hypothalamus (right)	56.7/2.2	50.0/0.7	50.7/1.1	11,8%	10,6%
Hypothalamus (left)	61.6/1.2	52.6/0.9	62.4/0.8	14,6%	-1,3%
Small Intestine 5 (right)	59.8/1.6	50.6/1.3	59.3/0.9	15,4%	0,8%
Small Intestine 5 (left)	57.1/2.6	55.7/1.0	54.2/1.0	2,5%	5,1%
Kidney 8 (right)	61.1/2.1	53.0/0.8	60.5/1.3	13,3%	1,0%
Kidney 8 (left)	57.0/2.6	58.1/0.0	56.5/1.6	-1,9%	0,9%
Large Intestine 4 (right)	59.2/0.9	50.5/0.5	56.7/1.8	14,7%	4,2%
Large Intestine 4 (left)	61.7/0.8	53.0/1.2	62.5/0.7	14,1%	-1,3%
Large Intestine 11 (right)	60.4/1.1	53.8/0.9	60.0/2.1	10,9%	0,7%
Large Intestine 11 (left)	59.7/0.7	54.4/1.4	57.4/1.2	8,9%	3,9%
Stomach 3 (right)	56.2/1.2	54.1/0.5	57.4/0.7	3,7%	-2,1%
Stomach 3 (left)	58.4/1.3	51.1/1.0	58.7/0.2	12,5%	-0,5%
Anxiety					
Conception Vessel 12	61.8/1.3	49.8/0.3	60,1	19,4%	2,8%
Liver 3 (right)	59.1/1.2	54.8/0.2	58.4/1.1	7,3%	1,2%
GV 16	57.0/0.9	50.3/1.1	58.6/0.2	11,8%	-2,8%
Eye Disorders					
Gbl 1 (right)	56.9/1.2	52.9/0.6	55.4/0.2	7,0%	2,6%
Gbl 1 (left)	55.2/1.2	52.7/0.7	55.8/0.8	4,5%	-1,1%
OR11 (left)	63.0/1.4	53.9/0.4	64.3/1.3	14,4%	-2,1%
OR10 (right)	63.9/1.0	52.5/0.8	62.9/1.0	17,8%	1,6%
OR 6 (right)	54.1/1.3	53.5/0.8	55.7/1.2	1,1%	-3,0%
OR 9 (left)	54.7/1.2	50.0/0.1	54.8/0.7	8,6%	-0,2%
CX1 -specific for blurred vision (right)	60.6/1.2	61.0/0.5	61.8/0.6	-0,7%	-2,0%
CX1 -specific for blurred vision (left)	63.5/0.9	50.8/0.8	65.8/1.4	20,0%	-3,6%
GB20 -specific for dull vision and eye fatigue (right)	64.1/0.9	53.4/1.1	64.4/0.6	16,7%	-0,5%
GB20 -specific for dull vision and eye fatigue (left)	65.3/1.0	51.1/0.7	66.7/1.4	21,7%	-2,1%
CX6 -specific for Glaucoma (right)	58.2/1.9	50.1/1.1	56.1/0.9	13,9%	3,6%
CX6 -specific for Glaucoma (left)	69.9/1.4	54.7/0.6	68.1/0.9	21,7%	2,6%
GV 23-2	61.7/3.2	51.7/0.9	62.6/0.7	16,2%	-1,5%
Stress					
H 6a (right)	57.0/0.8	56.8/0.4	56.8/1.3	0,4%	0,4%
H 6a (left)	60.0/1.0	51.8/1.0	59.1/0.7	13,7%	1,5%
Gbl 19a (left)	60.2/1.1	53.7/0.9	60.4/41.1	10,8%	-0,3%
Gbl 19a (right)	62.1/1.6	53.4/0.4	58.9/1.6	14,0%	5,2%
St36 (right)	56.2/0.3	50.7/0.5	58.2/0.7	9,8%	-3,6%
St36 (left)	58.8/1.8	54.7/0.7	57.9/0.7	7,0%	1,5%

UB34 (right)	58.1/2.5	48.9/0.6	56.3/0.2	15,8%	3,1%
UB34 (left)	59.2/1.3	55.1/0.6	59.9/0.5	6,9%	-1,2%
Migraine					
GV 23-2 -eye pain/ migraine	61.7/3.2	51.7/0.9	62.6/0.7	16,2%	-1,5%
Gbl-1 (right) eye disorders/ migraine	56.9/1.2	52.9/0.6	55.4/0.2	7,0%	2,6%
Gbl-1(left) eye disorders/migraine	55.2/1.2	52.7/0.7	55.8/0.8	4,5%	-1,1%
GV 16 anxiety/migraine	57.0/0.9	50.3/1.1	58.6/0.2	11,8%	-2,8%
Name: #17					
		Set 17-1	Set 17-2		
Points Tested:	Peak / Drop	Peak / Drop	Peak / Drop	% of Change	% of Change
Mental Focus	Baseline	Active	Placebo		
Hypothalamus (right)	62.3/1.3	51.7/1.4	63.1/0.7	17,0%	-1,3%
Hypothalamus (left)	64.6/1.7	54.7/1.5	66.2/0.4	15,3%	-2,5%
Small Intestine 5 (right)	60.9/1.0	57.2/1.4	65.6/0.8	6,1%	-7,7%
Small Intestine 5 (left)	69.3/1.6	51.1/0.3	67.1/0.7	26,3%	3,2%
Kidney 8 (right)	63.8/1.4	52.8/0.5	63.6/0.4	17,2%	0,3%
Kidney 8 (left)	66.5/1.2	52.8/1.2	63.8/0.8	20,6%	4,1%
Large Intestine 4 (right)	66.3/1.4	51.1/1.0	63.8/0.8	22,9%	3,8%
Large Intestine 4 (left)	69.0/1.7	51.7/1.0	65.9/0.6	25,1%	4,5%
Large Intestine 11 (right)	59.6/0.3	53.9/1.0	57.3/0.6	9,6%	3,9%
Large Intestine 11 (left)	65.9/0.9	50.4/0.6	64.7/1.7	23,5%	1,8%
Stomach 3 (right)	59.9/1.2	55.2/0.6	60.4/0.4	7,8%	-0,8%
Stomach 3 (left)	63.7/0.9	50.1/0.9	66.4/0.9	21,4%	-4,2%
Anxiety					
Conception Vessel 12	60.9/0.9	51.2/0.6	60.6/0.5	15,9%	0,5%
Liver 3 (right)	59.9/0.4	50.2/1.2	59.7/1.6	16,2%	0,3%
GV 16	69.4/3.1	52.1/1.0	69.1/0.9	24,9%	0,4%
Eye Disorders					
Gbl 1 (right)	63.0/1.5	50.1/0.9	63.3/0.9	20,5%	-0,5%
Gbl 1 (left)	59.8/0.9	53.6/1.5	59.8/1.0	10,4%	0,0%
OR11 (left)	73.2/1.0	54.2/0.7	71.2/0.6	26,0%	2,7%
OR10 (right)	71.9/0.6	50.4/0.2	68.3/0.7	29,9%	5,0%
OR 6 (right)	62.6/0.9	56.4/0.5	65.1/1.0	9,9%	-4,0%
OR 9 (left)	62.0/0.8	52.9/0.4	63.7/0.9	14,7%	-2,7%
CX1 -specific for blurred vision (right)	68.7/0.7	48.6/0.3	67.5/1.4	29,3%	1,7%
CX1 -specific for blurred vision (left)	63.3/0.9	52.0/0.7	64.0/0.7	17,9%	-1,1%

GB20 -specific for dull vision and eye fatigue (right)	64.0/0.8	49.7/1.0	64.4/0.8	22,3%	-0,6%
GB20 -specific for dull vision and eye fatigue (left)	64.7/1.1	48.8/0.1	64.6/1.1	24,6%	0,2%
CX6 -specific for Glaucoma (right)	57.6/1.1	54.2/0.4	57.4/1.5	5,9%	0,3%
CX6 -specific for Glaucoma (left)	61.4/1.1	53.0/1.5	60.9/0.7	13,7%	0,8%
GV 23-2	69.9/1.0	54.0/0.4	70.3/0.8	22,7%	-0,6%
Stress					
H 6a (right)	70.2/1.6	56.3/0.4	72.4/0.6	19,8%	-3,1%
H 6a (left)	64.6/0.6	56.6/0.8	66.6/0.4	12,4%	-3,1%
Gbl 19a (left)	57.9/1.3	50.4/0.6	58.2/0.7	13,0%	-0,5%
Gbl 19a (right)	59.5/1.2	49.7/0.7	60.8/0.8	16,5%	-2,2%
St36 (right)	68.8/1.8	54.8/0.3	66.7/0.5	20,3%	3,1%
St36 (left)	63.8/0.3	53.7/1.1	66.2/1.3	15,8%	-3,8%
UB34 (right)	67.6/1.2	62.4/0.9	67.2/0.6	7,7%	0,6%
UB34 (left)	61.0/0.6	59.2/1.7	59.6/0.6	3,0%	2,3%
Migraine					
GV 23-2 -eye pain/ migraine	69.9/1.0	54.0/0.4	70.3/0.8	22,7%	-0,6%
Gbl-1 (right) eye disorders/ migraine	63.0/1.5	50.1/0.9	63.3/0.9	20,5%	-0,5%
Gbl-1(left) eye disorders/migraine	59.8/0.9	53.6/1.5	59.8/1.0	10,4%	0,0%
GV 16 anxiety/migraine	69.4/3.1	52.1/1.0	69.1/0.9	24,9%	0,4%
Name: #18 Male					
		Set 18-1	Set 18-2		
Points Tested:	Peak / Drop	Peak / Drop	Peak / Drop	% of Change	% of Change
Mental Focus		Baseline	Placebo	Active	
Hypothalamus (right)	50.9/0.5	53.2/0.7	51.7/0.4	-1,6%	-4,5%
Hypothalamus (left)	50.8/0.6	51.6/0.4	49.1/0.3	3,3%	-1,6%
Small Intestine 5 (right)	48.7/0.5	50.4/0.7	52.0/1.1	-6,8%	-3,5%
Small Intestine 5 (left)	49.5/0.8	50.2/0.6	54.6/0.5	-10,3%	-1,4%
Kidney 8 (right)	49.6/0.8	51.5/0.5	49.9/0.4	-0,6%	-3,8%
Kidney 8 (left)	61.5/4.3	50.4/0.4	50.0/0.7	18,7%	18,0%
Large Intestine 4 (right)	64.8/4.0	52.2/0.7	53.9/1.7	16,8%	19,4%
Large Intestine 4 (left)	54.9/1.2	48.5/0.4	49.6/0.3	9,7%	11,7%
Large Intestine 11 (right)	51.6/0.7	49.3/0.4	52.1/1.1	-1,0%	4,5%
Large Intestine 11 (left)	52.1/0.6	51.6/0.9	51.0/0.8	2,1%	1,0%
Stomach 3 (right)	53.1/0.6	49.1/0.7	50.2/0.3	5,5%	7,5%
Stomach 3 (left)	52.4/1.2	48.7/0.4	49.8/0.5	5,0%	7,1%
Anxiety					

Conception Vessel 12	50.5/0.7	50.7/0.3	50.0/0.2	-0,4%	1,0%
Liver 3 (right)	58.1/1.8	49.3/0.5	51.2/1.3	11,9%	15,1%
GV 16	58.1/1.0	49.3/0.5	52.7/1.0	9,3%	15,1%
Eye Disorders					
Gbl 1 (right)	57.8/2.0	49.9/0.7	51.5/0.8	10,9%	13,7%
Gbl 1 (left)	51.8/1.1	50.8/0.7	50.6/1.5	2,3%	1,9%
OR11 (left)	61.2/0.5	48.4/0.7	49.6/1.1	19,0%	20,9%
OR10 (right)	58.3/1.1	50.0/0.8	51.0/0.2	12,5%	14,2%
OR 6 (right)	55.2/1.0	50.1/0.5	49.9/0.3	9,6%	9,2%
OR 9 (left)	54.1/0.3	50.3/1.1	50.1/0.7	7,4%	7,0%
CX1 -specific for blurred vision (right)	50.5/0.7	50.2/0.3	50.8/0.9	0,6%	-0,6%
CX1 -specific for blurred vision (left)	50.8/0.7	51.2/0.3	49.7/0.7	-0,8%	2,2%
GB20 -specific for dull vision and eye fatigue (right)	54.7/0.9	52.9/0.3	49.7/0.4	3,3%	9,1%
GB20 -specific for dull vision and eye fatigue (left)	50.1/0.2	51.0/0.5	50.5/0.3	-1,8%	-0,8%
CX6 -specific for Glaucoma (right)	53.1/0.2	51.3/0.7	53.3/0.8	3,4%	-0,4%
CX6 -specific for Glaucoma (left)	52.9/0.4	53.5/0.8	50.7/0.4	-1,1%	4,2%
GV 23-2	58.5/0.2	50.4/0.7	50,2	14,2%	13,8%
Stress					
H 6a (right)	55.4/0.6	59.7/0.7	49.7/0.2	10,3%	-7,8%
H 6a (left)	51.5/1.1	49.4/0.5	51.6/0.9	4,1%	-0,2%
Gbl 19a (left)	57.6/0.9	51.6/0.7	51.9/1.0	10,4%	9,9%
Gbl 19a (right)	55.9/0.8	50.4/1.3	50.4/0.7	9,8%	9,8%
St36 (right)	51.7/0.7	52.1/0.5	50.0/0.7	-0,8%	3,3%
St36 (left)	58.5/1.9	49.9/0.8	49.9/0.5	14,7%	14,7%
UB34 (right)	54.6/1.-	51.1/1.1	51.3/0.6	6,4%	6,0%
UB34 (left)	58.7/1.2	50.0/0.6	50.4/0.7	14,8%	14,1%
Migraine					
GV 23-2 -eye pain/ migraine	58.5/2.2.2	50.4/0.7	50,2	13,8%	14,2%
Gbl-1 (right) eye disorders/ migraine	57.8/2.0	49.9/0.7	51.5/0.8	13,7%	10,9%
Gbl-1(left) eye disorders/migraine	51.8/1.1	50.8/0.7	50.6/1.5	1,9%	2,3%
GV 16 anxiety/migraine	58.1/1.0	49.3/0.5	52.7/1.0	15,1%	9,3%
Name: #19					
		Set 19-1	Set 19-2		
Points Tested:	Peak / Drop	Peak / Drop	Peak / Drop	% of Change	% of Change
Mental Focus		Baseline	Active	Placebo	
Hypothalamus (right)	79.1/0.8	78.1/1.9	79.8/1.6	1,3%	-0,9%

Hypothalamus (left)	75.2/1.2	66.8/1.0	72.6/0.7	11,2%	3,5%
Small Intestine 5 (right)	71.9/0.5	62.2/1.5	74.0/0.8	13,5%	-2,9%
Small Intestine 5 (left)	72.5/0.6	56.1/0.5	67.7/0.7	22,6%	6,6%
Kidney 8 (right)	68.7/1.1	57.0/1.4	68.7/1.4	17,0%	0,0%
Kidney 8 (left)	70.3/0.6	58.6/1.0	63.8/1.0	16,6%	9,2%
Large Intestine 4 (right)	71.2/0.6	58.2/0.7	70.1/0.8	18,3%	1,5%
Large Intestine 4 (left)	72.2/0.7	61.7/1.2	67.5/1.4	14,5%	6,5%
Large Intestine 11 (right)	72.3/0.7	63.8/1.2	63.9/0.9	11,8%	11,6%
Large Intestine 11 (left)	73.3/1.0	57.2/1.6	65.5/2.0	22,0%	10,6%
Stomach 3 (right)	70.9/0.9	61.7/1.7	64.9/1.3	13,0%	8,5%
Stomach 3 (left)	72.7/0.7	60.4/0.4	65.6/1.1	16,9%	9,8%
Anxiety					
Conception Vessel 12	66.2/0.5	53.2/0.3	65.9/0.2	19,6%	0,5%
Liver 3 (right)	65.0/1.9	57.0/2.1	63.6/2.5	12,3%	2,2%
GV 16	73.1/0.2	59.0/2.3	64.2/0.6	19,3%	12,2%
Eye Disorders					
Gbl 1 (right)	62.1/1.1	60.8/1.6	68.2/1.5	2,1%	-9,8%
Gbl 1 (left)	64.7/1.2	62.6/1.1	68.9/1.4	3,2%	-6,5%
OR11 (left)	62.2/1.4	60.2/1.1	74.7/1.1	3,2%	-20,1%
OR10 (right)	67.9/1.4	69.1/1.7	71.7/0.7	-1,8%	-5,6%
OR 6 (right)	56.8/1.5	66.2/1.8	64.9/1.2	-16,5%	-14,3%
OR 9 (left)	61.2/1.6	62.3/1.4	76.4/1.3	-1,8%	-24,8%
CX1 -specific for blurred vision (right)	66.2/0.7	61.2/0.9	64.9/0.7	7,6%	2,0%
CX1 -specific for blurred vision (left)	68.1/0.3	61.2/0.3	67.6/0.9	10,1%	0,7%
GB20 -specific for dull vision and eye fatigue (right)	65.1/0.9	61.3/0.7	66.0/0.2	5,8%	-1,4%
GB20 -specific for dull vision and eye fatigue (left)	68.1/0.3	59.2/0.3	67.9/0.5	13,1%	0,3%
CX6 -specific for Glaucoma (right)	66.7/0.5	62.3/0.9	67.1/0.3	6,6%	-0,6%
CX6 -specific for Glaucoma (left)	65.2/0.5	61.1/0.7	66.1/0.9	6,3%	-1,4%
GV 23-2	66.7/1.5	58.3/2.0	74.4/0.1	12,6%	-11,5%
Stress					
H 6a (right)	71.8/2.8	65.7/1.1	70.8/1.3	8,5%	1,4%
H 6a (left)	69.2/0.5	61.4/1.2	70.4/1.1	11,3%	-1,7%
Gbl 19a (left)	64.4/0.7	64.4/1.0	67.4/1.5	0,0%	-4,7%
Gbl 19a (right)	59.9/0.8	59.0/1.7	66.0/2.5	1,5%	-10,2%
St36 (right)	64.4/0.9	64.0/1.3	65.9/0.6	0,6%	-2,3%
St36 (left)	61.6/1.0	59.6/1.8	68.5/1.1	3,2%	-11,2%
UB34 (right)	59.2/2.4	56.1/2.2	64.8/1.3	5,2%	-9,5%

UB34 (left)	69.2/2.4	69.0/2.2	71.7/0.7	0,3%	-3,6%
Migraine					
GV 23-2 -eye pain/ migraine	66.7/1.5	58.3/2.0	74.4/0.1	12,6%	-11,5%
Gbl-1 (right) eye disorders/ migraine	62.1/1.1	60.8/1.6	68.2/1.5	2,1%	-9,8%
Gbl-1(left) eye disorders/migraine	64.7/1.2	62.6/1.1	68.9/1.4	3,2%	-6,5%
GV 16 anxiety/migraine	73.1/0.2	59.0/2.3	64.2/0.6	19,3%	12,2%
Name: #20					
		Set 20-1	Set 20-2		
Points Tested:	Peak / Drop	Peak / Drop	Peak / Drop	% of Change	% of Change
Mental Focus	Baseline	Active	Placebo		
Hypothalamus (right)	75.6/0.6	77.0/0.4	77.2/3.0	-1,9%	-2,1%
Hypothalamus (left)	81.5/1.0	61.8/0.5	75.5/0.8	24,2%	7,4%
Small Intestine 5 (right)	78.2/1.1	63.1/0.2	72.3/0.9	19,3%	7,5%
Small Intestine 5 (left)	78.0/1.0	61.7/0.5	72.9/0.6	20,9%	6,5%
Kidney 8 (right)	75.1/0.6	58.0/0.7	70.3/0.6	22,8%	6,4%
Kidney 8 (left)	76.1/0.7	67.4/0.8	70.9/0.3	11,4%	6,8%
Large Intestine 4 (right)	73.9/0.6	61.9/0.6	69.2/0.4	16,2%	6,4%
Large Intestine 4 (left)	74.9/0.6	56.4/0.8	64.7/0.5	24,7%	13,6%
Large Intestine 11 (right)	77.8/0.5	56.7/0.6	72.2/0.5	27,1%	7,2%
Large Intestine 11 (left)	77.3/0.5	53.8/0.4	70.4/2.0	30,4%	8,9%
Stomach 3 (right)	74.2/0.5	58.0/0.7	66.4/1.1	21,8%	10,5%
Stomach 3 (left)	75.9/0.4	57.2/0.8	60.2/0.9	24,6%	20,7%
Anxiety					
Conception Vessel 12	56.3/1.0	51.5/0.5	71.9/0.9	9,4%	-27,7%
Liver 3 (right)	75.3/0.7	52.7/0.7	72.2/0.7	30,0%	4,1%
GV 16	76.5/0.8	57.4/0.8	69.0/0.8	25,0%	9,8%
Eye Disorders					
Gbl 1 (right)	77.1/0.6	64.6/1.2	71.3/0.5	16,2%	7,5%
Gbl 1 (left)	75.7/0.7	59.1/0.6	72.8/0.8	21,9%	3,8%
OR11 (left)	75.9/0.6	57.0/1.0	73.3/0.3	24,9%	3,4%
OR10 (right)	74.0/0.4	53.5/0.3	70.4/0.5	27,7%	4,9%
OR 6 (right)	69.4/0.5	62.2/0.5	68.8/0.4	10,4%	0,9%
OR 9 (left)	70.7/0.7	57.7/0.6	66.9/0.3	18,4%	5,4%
CX1 -specific for blurred vision (right)	53.9/0.6	51.2/1.0	63.4/1.5	5,0%	-17,6%
CX1 -specific for blurred vision (left)	61.3/0.9	50.0/0.4	59.9/0.5	18,4%	2,3%
GB20 -specific for dull vision and eye fatigue (right)	61.8/1.1	52.3/0.6	55.2/0.4	15,4%	10,7%

GB20 -specific for dull vision and eye fatigue (left)	56.6/0.8	49.6/0.8	57.5/0.8	12,4%	-1,6%
CX6 -specific for Glaucoma (right)	58.7/0.4	50.2/0.6	58.4/0.8	14,5%	0,5%
CX6 -specific for Glaucoma (left)	60.2/1.2	49.7/0.6	60.3/0.9	17,4%	-0,2%
GV 23-2	70.7/1.0	61.0/1.5	68.6/0.9	13,7%	3,0%
Stress					
H 6a (right)	72.5/0.6	57.9/0.8	69.5/1.1	20,1%	4,1%
H 6a (left)	73.8/0.7	58.1/0.5	67.7/0.2	21,3%	8,3%
Gbl 19a (left)	70.4/1.0	61.5/0.4	61.8/0.1	12,6%	12,2%
Gbl 19a (right)	68.2/0.8	60.2/1.6	58.2/0.3	11,7%	14,7%
St36 (right)	74.2/0.7	59.4/0.7	73.4/0.9	19,9%	1,1%
St36 (left)	71.8/0.6	61.4/0.3	72.5/0.6	14,5%	-1,0%
UB34 (right)	70.3/0.7	55.2/0.1	70.7/0.8	21,5%	-0,6%
UB34 (left)	74.7/1.0	56.9/0.5	70.3/0.4	23,8%	5,9%
Migraine					
GV 23-2 -eye pain/ migraine	70.7/1.0	61.0/1.5	69.2/0.3	13,7%	2,1%
Gbl-1 (right) eye disorders/ migraine	77.1/0.6	64.6/1.2	71.3/0.5	16,2%	7,5%
Gbl-1(left) eye disorders/migraine	75.7/0.7	59.1/0.6	72.8/0.8	21,9%	3,8%
GV 16 anxiety/migraine	76.5/0.8	57.4/0.8	69.0/0.8	25,0%	9,8%
Name: #21					
		Set 21-1	Set 21-2		
Points Tested:	Peak / Drop	Peak / Drop	Peak / Drop	% of Change	% of Change
Mental Focus		Baseline	Placebo	Active	
Hypothalamus (right)	60.4/0.6	58.7/0.8	54.1/0.5	10,4%	2,8%
Hypothalamus (left)	57.5/0.8	53.5/0.5	51.1/0.9	11,1%	7,0%
Small Intestine 5 (right)	61.8/0.4	64.8/0.7	64.4/2.3	-4,2%	-4,9%
Small Intestine 5 (left)	59.5/0.2	57.4/0.7	48.2/0.8	19,0%	3,5%
Kidney 8 (right)	65.7/1.0	61.2/1.3	49.8/1.3	24,2%	6,8%
Kidney 8 (left)	60.8/0.7	56.4/0.9	51.7/0.3	15,0%	7,2%
Large Intestine 4 (right)	60.1/0.9	55.6/0.2	62.1/1.5	-3,3%	7,5%
Large Intestine 4 (left)	68.1/2.4	56.0/0.7	53.7/0.6	21,1%	17,8%
Large Intestine 11 (right)	59.5/1.0	54.9/0.7	56.3/1.0	5,4%	7,7%
Large Intestine 11 (left)	54.8/0.8	53.6/0.6	59.0/1.5	-7,7%	2,2%
Stomach 3 (right)	60.0/0.5	58.4/0.8	53.6/1.2	10,7%	2,7%
Stomach 3 (left)	62.7/1.1	59.4/1.0	53.6/0.9	14,5%	5,3%
Anxiety					
Conception Vessel 12	58.3/0.5	57.9/0.3	54.2/0.9	10,0%	-5,8%

Liver 3 (right)	55.3/0.4	56.1/0.8	56.5/0.1	-2,2%	-1,4%
GV 16	56.7/0.5	56.1/0.8	53.5/0.3	5,6%	1,1%
Eye Disorders					
Gbl 1 (right)	57.4/0.7	53.7/0.6	52.4/0.2	8,7%	6,4%
Gbl 1 (left)	55.0/0.6	50.5/0.3	57.4/1.1	-4,4%	8,2%
OR11 (left)	59.8/0.4	57.2/1.3	62.0/3.0	-3,7%	4,3%
OR10 (right)	58.9/1.0	55.0/0.4	63.1/2.1	-7,1%	6,6%
OR 6 (right)	54.1/0.9	58.3/0.9	60.1/1.3	-11,1%	-7,8%
OR 9 (left)	54.0/0.4	61.7/0.7	55.3/1.3	-2,4%	-14,3%
CX1 -specific for blurred vision (right)	71,7	53,2	50,5	29,6%	25,8%
CX1 -specific for blurred vision (left)	58,6	59,7	50,4	14,0%	-1,9%
GB20 -specific for dull vision and eye fatigue (right)	61,0	53,1	54,5	10,7%	13,0%
GB20 -specific for dull vision and eye fatigue (left)	63,4	52,4	61,2	3,5%	17,4%
CX6 -specific for Glaucoma (right)	60,2	51,7	55,1	8,5%	14,1%
CX6 -specific for Glaucoma (left)	58,6	56,4	57,1	2,6%	3,8%
GV 23-2	56,8	55,4	55,8	1,8%	2,5%
Stress					
H 6a (right)	64.1/0.9	53.6/0.7	52.0/1.0	18,9%	16,4%
H 6a (left)	72.2/2.2	53.4/0.9	59.2/1.9	18,0%	26,0%
Gbl 19a (left)	60.0/2.4	54.8/1.5	56.3/1.6	6,2%	8,7%
Gbl 19a (right)	61.1/0.7		58.9/1.7	3,6%	100,0%
St36 (right)	59.6/2.0	49.9/0.8	57.3/0.6	3,9%	16,3%
St36 (left)	56.9/0.9		52.5/0.6	7,7%	100,0%
UB34 (right)	71.3/1.0		62.5/1.2	12,3%	100,0%
UB34 (left)	62.5/0.8	54.7/0.5	57.9/1.8	7,4%	12,5%
Migraine					
GV 23-2 -eye pain/ migraine	56.8/1.9	55.4/0.5	55.8/1.8	1,8%	2,5%
Gbl-1 (right) eye disorders/ migraine	57.4/0.7	53.7/0.6	52.4/0.2	8,7%	6,4%
Gbl-1(left) eye disorders/migraine	55.0/0.6	50.5/0.3	57.4/1.1	-4,4%	8,2%
GV 16 anxiety/migraine	56.7/0.5	56.1/0.8	53.5/0.3	5,6%	1,1%
Name: #22 female					
		Set 22-1	Set 22-2		
Points Tested:	Peak / Drop	Peak / Drop	Peak / Drop	% of Change	% of Change
Mental Focus		Baseline	Placebo	Active	
Hypothalamus (right)	55.9/0.8	60.7/1.7	50.0/0.7	10,6%	-8,6%
Hypothalamus (left)	54.0/0.6	57.9/0.6	50.6/0.7	6,3%	-7,2%

Small Intestine 5 (right)	61.2/0.8	57.5/1.4	52.9/1.0	13,6%	6,0%
Small Intestine 5 (left)	57.1/0.9	58.9/1.1	55.3/0.7	3,2%	-3,2%
Kidney 8 (right)	57.5/1.0	59.7/0.2	52.5/0.6	8,7%	-3,8%
Kidney 8 (left)	57.0/0.6	56.4/0.4	51.5/0.6	9,6%	1,1%
Large Intestine 4 (right)	52.3/0.6	53.7/0.9	51.2/0.7	2,1%	-2,7%
Large Intestine 4 (left)	53.5/1.3	51.4/0.6	51.5/0.4	3,7%	3,9%
Large Intestine 11 (right)	56.5/2.2	56.7/0.7	51.1/0.7	9,6%	-0,4%
Large Intestine 11 (left)	61.6/0.7	59.1/0.7	51.8/0.6	15,9%	4,1%
Stomach 3 (right)	61.3/1.1	60.6/0.4	49.9/0.5	18,6%	1,1%
Stomach 3 (left)	59.6/1.1	55.5/0.5	50.1/0.6	15,9%	6,9%
Anxiety					
Conception Vessel 12	60.0/0.5	59.3/0.6	49.5/0.3	17,5%	1,2%
Liver 3 (right)	61.4/0.7	60.1/0.5	51.0/0.7	16,9%	2,1%
GV 16	62.1/1.1	60.6/0.5	51.5/0.6	17,1%	2,4%
Eye Disorders					
Gbl 1 (right)	57.1/2.0	57.0/0.8	50.1/0.7	12,3%	0,2%
Gbl 1 (left)	57.4/1.1	57.7/0.6	50.6/0.9	11,8%	-0,5%
OR11 (left)	58.9/1.6	57.4/0.7	55.3/0.9	6,1%	2,5%
OR10 (right)	60.5/1.1	59.1/0.6	56.4/0.4	6,8%	2,3%
OR 6 (right)	60.1/1.2	59.8/0.5	50.5/0.3	16,0%	0,5%
OR 9 (left)	57.2/0.7	57.7/1.9	53.6/0.7	6,3%	-0,9%
CX1 -specific for blurred vision (right)	53.3/0.3	55.2/0.4	48.7/1.1	8,6%	-3,6%
CX1 -specific for blurred vision (left)	60.3/0.9	58.8/0.7	54.2/1.0	10,1%	2,5%
GB20 -specific for dull vision and eye fatigue (right)	60.5/0.3	60.0/0.4	50.3/0.8	16,9%	0,8%
GB20 -specific for dull vision and eye fatigue (left)	59.8/0.4	60.1/0.3	50.0/0.6	16,4%	-0,5%
CX6 -specific for Glaucoma (right)	60.6/1.0	59.3/0.6	52.0/0.6	14,2%	2,1%
CX6 -specific for Glaucoma (left)	60.2/0.7	59.3/0.7	50.4/0.8	16,3%	1,5%
GV 23-2	62.5/1.5	61.2/0.9	50.9/0.3	18,6%	2,1%
Stress					
H 6a (right)	62.2/0.9	63.0/0.6	53.9/0.9	13,3%	-1,3%
H 6a (left)	56.2/1.1	58.6/0.6	54.5/0.9	3,0%	-4,3%
Gbl 19a (left)	58.7/0.8	58.9/0.7	52.0/0.9	11,4%	-0,3%
Gbl 19a (right)	58.1/0.6	57.4/0.3	52.3/1.1	10,0%	1,2%
St36 (right)	58.3/0.6	58.3/1.1	54.1/0.9	7,2%	0,0%
St36 (left)	59.2/1.0	57.1/0.5	49.4/0.7	16,6%	3,5%
UB34 (right)	58.8/0.7	58.3/0.5	52.7/0.6	10,4%	0,9%
UB34 (left)	55.9/0.7	57.7/0.4	50.0/0.6	10,6%	-3,2%

Migraine					
GV 23-2 -eye pain/ migraine	62.5/1.5	61.2/0.9	50.9/0.3	18,6%	2,1%
Gbl-1 (right) eye disorders/ migraine	57.1/2.0	57.0/0.8	50.1/0.7	12,3%	0,2%
Gbl-1(left) eye disorders/migraine	57.4/1.1	57.7/0.6	50.6/0.9	11,8%	-0,5%
GV 16 anxiety/migraine	62.1/1.1	60.6/0.5	51.5/0.6	17,1%	2,4%
Name: #23 female					
Points Tested:	Peak / Drop	Peak / Drop	Peak / Drop	% of Change	% of Change
Mental Focus	Baseline	Placebo	Active		
Hypothalamus (right)	61.8/0.7	60.2/0.7	51.5/0.6	16,7%	2,6%
Hypothalamus (left)	59.8/0.6	60.9/0.4	54.8/0.6	8,4%	-1,8%
Small Intestine 5 (right)	59.2/0.6	60.1/0.9	55.8/0.6	6,7%	-0,5%
Small Intestine 5 (left)	55.9/0.2	56.0/0.1	53.2/0.3	4,8%	-0,2%
Kidney 8 (right)	56.4/0.9	58.0/0.8	51.7/0.5	8,3%	-2,8%
Kidney 8 (left)	58.5/0.7	57.0/0.5	52.1/0.5	10,9%	2,6%
Large Intestine 4 (right)	57.0/0.2	57.5/0.4	51.3/0.4	10,0%	-0,9%
Large Intestine 4 (left)	63.8/1.3	63.8/0.7	50.6/0.8	20,7%	0,0%
Large Intestine 11 (right)	60.2/0.6	62.6/0.6	51.5/0.5	14,5%	-4,0%
Large Intestine 11 (left)	58.4/0.5	60.5/0.8	53.5/0.7	8,4%	-3,6%
Stomach 3 (right)	61.0/0.9	62.1/0.4	51.6/0.7	15,4%	-1,8%
Stomach 3 (left)	65.2/0.6	64.2/0.5	51.2/0.8	21,5%	1,5%
Anxiety					
Conception Vessel 12	61.3/0.7	60.9/0.4	51.1/0.6	16,6%	0,7%
Liver 3 (right)	60.9/0.4	61.0/0.5	51.1/0.2	16,1%	-0,2%
GV 16	55.7/0.2	56.5/0.4	54.1/0.7	2,9%	-1,4%
Eye Disorders					
Gbl 1 (right)	60.4/0.8	59.3/0.6	52.0/0.6	13,9%	1,8%
Gbl 1 (left)	64.7/0.5	64.7/0.7	51.6/0.5	20,2%	0,0%
OR11 (left)	64.0/1.2	65.3/0.3	51.3/0.5	19,8%	-2,0%
OR10 (right)	66.5/1.0	64.4/0.7	51.1/0.4	23,2%	3,2%
OR 6 (right)	61.2/1.1	60.0/0.7	54.5/0.3	10,9%	2,0%
OR 9 (left)	61.4/0.6	60.3/0.4	56.3/0.3	8,3%	1,8%
CX1 -specific for blurred vision (right)	55.0/0.9	56.2/0.6	51.2/0.6	6,9%	-2,2%
CX1 -specific for blurred vision (left)	57.9/1.4	56.5/1.0	50.6/0.8	12,6%	2,4%
GB20 -specific for dull vision and eye fatigue (right)	59.5/0.6	60.9/0.6	51.2/0.3	13,9%	-2,4%
GB20 -specific for dull vision and eye fatigue (left)	61.8/0.6	60.4/0.8	51.6/0.3	16,5%	2,3%

CX6 -specific for Glaucoma (right)	59.8/0.3	58.2/0.2	52.7/0.8	11,9%	2,7%
CX6 -specific for Glaucoma (left)	62.8/0.8	63.3/0.5	51.2/0.5	18,5%	-0,8%
GV 23-2	62.3/1.8	62.2/0.6	53.2/0.5	14,6%	0,2%
Stress					
H 6a (right)	63.8/0.8	64.4/0.7	53.0/0.5	16,9%	-0,9%
H 6a (left)	61.7/0.8	61.0/0.6	52.0/0.9	15,7%	1,1%
Gbl 19a (left)	59.4/0.4	60.8/0.5	54.3/0.2	8,6%	-2,4%
Gbl 19a (right)	60.3/0.3	61.9/0.8	52.1/0.5	13,6%	-2,7%
St36 (right)	62.3/0.2	60.2/0.4	52.9/0.1	15,1%	3,4%
St36 (left)	64.4/0.9	61.6/0.4	52.5/0.1	18,5%	4,3%
UB34 (right)	62.3/0.6	61.8/0.8	51.8/0.4	16,9%	0,8%
UB34 (left)	61.2/1.1	60.2/0.3	49.8/1.0	18,6%	1,6%
Migraine					
GV 23-2 -eye pain/ migraine	62.3/1.8	62.2/0.6	53.2/0.5	14,6%	0,2%
Gbl-1 (right) eye disorders/ migraine	60.4/0.8	59.3/0.6	52.0/0.6	13,9%	1,8%
Gbl-1(left) eye disorders/migraine	64.7/0.5	64.7/0.7	51.6/0.5	20,2%	0,0%
GV 16 anxiety/migraine	55.7/0.2	56.5/0.4	54.1/0.7	2,9%	-1,4%
Name: #24 male					
		Set 24-1	Set 24-2		
Points Tested:	Peak / Drop	Peak / Drop	Peak / Drop	% of Change	% of Change
Mental Focus		Baseline	Active	Placebo	
Hypothalamus (right)	59.2/0.6	50.2/0.2	60.6/0.1	15,2%	-2,4%
Hypothalamus (left)	62.1/0.3	53.5/1.1	60.9/0.4	13,8%	1,9%
Small Intestine 5 (right)	63.4/0.4	52.2/0.9	63.3/0.9	17,7%	0,2%
Small Intestine 5 (left)	61.6/0.4	51.4/0.4	63.4/0.7	16,6%	-2,9%
Kidney 8 (right)	68.4/2.0	52.4/0.4	66.1/1.5	23,4%	3,4%
Kidney 8 (left)	66.2/1.3	54.3/0.9	64.7/1.3	18,0%	2,3%
Large Intestine 4 (right)	56.5/0.6	53.5/0.8	56.8/0.7	5,3%	-0,5%
Large Intestine 4 (left)	57.3/0.5	55.1/0.6	60.3/1.0	3,8%	-5,2%
Large Intestine 11 (right)	62.1/0.8	51.4/0.4	61.9/0.2	17,2%	0,3%
Large Intestine 11 (left)	61.6/0.6	50.1/0.4	60.6/0.2	18,7%	1,6%
Stomach 3 (right)	61.8/1.5	53.8/0.9	63.0/0.9	12,9%	-1,9%
Stomach 3 (left)	59.9/0.9	52.8/0.5	58.6/0.3	11,9%	2,2%
Anxiety					
Conception Vessel 12	62.1/0.6	49.6/0.9		20,1%	
Liver 3 (right)	63.4/0.6	51.2/0.7	61.2/0.6	19,2%	3,5%

GV 16	64.1/1.1	55.5/0.1	61.9/0.7	13,4%	3,4%
Eye Disorders					
Gbl 1 (right)	62.0/0.6	54.3/0.9	62.7/0.3	12,4%	-1,1%
Gbl 1 (left)	56.2/0.5	54.3/0.9	56.5/0.7	3,4%	-0,5%
OR11 (left)	61.2/2.5	52.8/0.8	61.3/0.6	13,7%	-0,2%
OR10 (right)	56.5/1.5	50.7/1.3	57.2/0.4	10,3%	-1,2%
OR 6 (right)	58.4/1.0	53.4/0.5	57.6/0.1	8,6%	1,4%
OR 9 (left)	61.1/0.3	51.2/0.3	60.9/0.6	16,2%	0,3%
CX1 -specific for blurred vision (right)	66.2/0.6	52.7/0.6	63.2/0.3	20,4%	4,5%
CX1 -specific for blurred vision (left)	60.0/0.6	57.6/0.8	60.2/0.9	4,0%	-0,3%
GB20 -specific for dull vision and eye fatigue (right)	60.2/0.7	52.7/0.5	60.3/0.5	12,5%	-0,2%
GB20 -specific for dull vision and eye fatigue (left)	62.1/0.7	50.5/0.6	61.7/0.9	18,7%	0,6%
CX6 -specific for Glaucoma (right)	61.1/0.6	52.3/1.0	60.7/0.6	14,4%	0,7%
CX6 -specific for Glaucoma (left)	64.1/0.9	51.5/0.8	60.9/1.1	19,7%	5,0%
GV 23-2	59.3/0.6	50.5/0.7	60.0/0.6	14,8%	-1,2%
Stress					
H 6a (right)	63.0/0.5	52.2/0.7	61.7/0.7	17,1%	2,1%
H 6a (left)	60.3/1.2	56.1/0.8	59.7/0.6	7,0%	1,0%
Gbl 19a (left)	61.3/0.7	53.5/1.2	60.2/0.4	12,7%	1,8%
Gbl 19a (right)	61.3/0.7	51.6/0.2	60.7/0.4	15,8%	1,0%
St36 (right)	63.3/1.2	52.7/1.1	62.2/0.4	16,7%	1,7%
St36 (left)	62.3/0.9	51.5/1.1	63.4/0.3	17,3%	-1,8%
UB34 (right)	60.5/2.0	53.5/0.8	60.9/0.4	11,6%	-0,7%
UB34 (left)	61.5/0.8	55.0/0.6	60.4/0.4	10,6%	1,8%
Migraine					
GV 23-2 -eye pain/ migraine	59.3/0.6	50.5/0.7	60.0/0.6	14,8%	-1,2%
Gbl-1 (right) eye disorders/ migraine	62.0/0.6	54.3/0.9	62.7/0.3	12,4%	-1,1%
Gbl-1(left) eye disorders/migraine	56.2/0.5	54.3/0.9	56.5/0.7	3,4%	-0,5%
GV 16 anxiety/migraine	64.1/1.1	55.5/0.1	61.9/0.7	13,4%	3,4%
Name: #25 male					
		Set 25-1	Set 25-2		
Points Tested:	Peak / Drop	Peak / Drop	Peak / Drop	% of Change	% of Change
Mental Focus	Baseline	Placebo	Active		
Hypothalamus (right)	54.4 / 0.5	56.6 / 1.0	55.3 / 0.8	-1,7%	-4,0%
Hypothalamus (left)	54.6 / 0.7	54.4 / 0.8	55.6 / 1.4	-1,8%	0,4%
Small Intestine 5 (right)	63.2 / 1.4	66.1 / 1.3	57.6 / 1.4	8,9%	-4,6%

Small Intestine 5 (left)	64.1 / 1.4	62.6 / 1.0	54.5 / 0.9	15,0%	2,3%
Kidney 8 (right)	60.9 / 0.8	59.0 / 0.4	61.2 / 0.9	-0,5%	3,1%
Kidney 8 (left)	62.9 / 1.2	63.0 / 0.4	53.9 / 1.1	14,3%	-0,2%
Large Intestine 4 (right)	57.2 / 0.4	58.5 / 0.6	51.6 / 0.7	9,8%	-2,3%
Large Intestine 4 (left)	63.2 / 1.7	62.2 / 0.9	54.6 / 1.3	13,6%	1,6%
Large Intestine 11 (right)	63.1 / 1.2	56.6 / 0.6	49.7 / 0.3	21,2%	10,3%
Large Intestine 11 (left)	56.6 / 0.8	56.7 / 1.1	52.5 / 0.9	7,2%	-0,2%
Stomach 3 (right)	56.9 / 0.4	57.5 / 0.7	55.6 / 1.0	2,3%	-1,1%
Stomach 3 (left)	60.1 / 1.8	57.6 / 0.6	54.1 / 1.1	10,0%	4,2%
Anxiety					
Conception Vessel 12	65.3 / 0.9	54.4 / 0.8	49.4 / 0.5	24,3%	16,7%
Liver 3 (right)	54.3 / 0.7	55.0 / 1.5	53.5 / 0.8	1,5%	-1,3%
GV 16	59.2 / 1.3	56.9 / 0.9	50.4 / 0.7	14,9%	3,9%
Eye Disorders					
Gbl 1 (right)	62.4 / 1.7	61.1 / 0.8	49.9 / 0.5	20,0%	2,1%
Gbl 1 (left)	58.4 / 1.6	59.7 / 0.7	53.2 / 0.9	8,9%	-2,2%
OR11 (left)	62.7 / 2.7	62.1 / 2.5	53.0 / 1.6	15,5%	1,0%
OR10 (right)	55.1 / 1.2	56.4 / 0.9	1.6 / 0.0	97,1%	-2,4%
OR 6 (right)	58.7 / 1.4	59.1 / 0.8	52.0 / 1.3	11,4%	-0,7%
OR 9 (left)	61.5 / 2.6	58.3 / 0.6	51.3 / 0.7	16,6%	5,2%
CX1 -specific for blurred vision (right)	64.1 / 0.9	50.4 / 1.0	50.7 / 0.7	20,9%	21,4%
CX1 -specific for blurred vision (left)	70.9 / 0.7	50.2 / 0.8	50.9 / 0.7	28,2%	29,2%
GB20 -specific for dull vision and eye fatigue (right)	61.0 / 0.2	50.3 / 0.8	51.5 / 0.5	15,6%	17,5%
GB20 -specific for dull vision and eye fatigue (left)	62.9 / 0.4	52.8 / 0.3	48.8 / 1.2	22,4%	16,1%
CX6 -specific for Glaucoma (right)	68.6 / 0.7	50.4 / 0.7	49.7 / 1.1	27,6%	26,5%
CX6 -specific for Glaucoma (left)	65.6 / 1.0	51.4 / 1.1	50.1 / 1.2	23,6%	21,6%
GV 23-2	72.4 / 0.7	69.4 / 0.7	55.1 / 0.9	23,9%	4,1%
Stress					
H 6a (right)	70.7 / 1.2	68.4 / 0.7	52.8 / 0.8	25,3%	3,3%
H 6a (left)	67.3 / 2.6	63.2 / 0.6	59.3 / 1.0	11,9%	6,1%
Gbl 19a (left)	67.0 / 1.2	64.2 / 0.5	55.9 / 0.6	16,6%	4,2%
Gbl 19a (right)	71.1 / 1.0	66.0 / 0.9	52.9 / 1.3	25,6%	7,2%
St36 (right)	62.8 / 1.2	59.8 / 0.8	57.6 / 0.7	8,3%	4,8%
St36 (left)	59.6 / 1.4	60.0 / 0.7	53.3 / 0.9	10,6%	-0,7%
UB34 (right)	58.5 / 0.9	60.9 / 2.4	53.3 / 1.0	8,9%	-4,1%
UB34 (left)	59.2 / 1.0	61.8 / 2.1	53.2 / 1.0	10,1%	-4,4%
Migraine					

GV 23-2 -eye pain/ migraine	72.4 / 0.7	69.4 / 0.7	55.1 / 0.9	23,9%	4,1%
Gbl-1 (right) eye disorders/ migraine	62.4 / 1.7	61.1 / 0.8	49.9 / 0.5	20,0%	2,1%
Gbl-1(left) eye disorders/migraine	58.4 / 1.6	59.7 / 0.7	53.2 / 0.9	8,9%	-2,2%
GV 16 anxiety/migraine	59.2 / 1.3	56.9 / 0.9	50.4 / 0.7	14,9%	3,9%
Name: #26 (Strait)		Set 26-1	Set 26-2		
Points Tested:	Peak / Drop	Peak / Drop	Peak / Drop	% of Change	% of Change
Mental Focus	Baseline	Placebo	Active		
Hypothalamus (right)	67.8 / 1.3	65.1 / 1.3	50.7 / 1.4	25,2%	4,0%
Hypothalamus (left)	69.2 / 0.2	66.0 / 1.0	59.1 / 0.9	14,6%	4,6%
Small Intestine 5 (right)	69.3 / 0.7	66.1 / 1.2	49.8 / 0.5	28,1%	4,6%
Small Intestine 5 (left)	67.5 / 0.3	65.0 / 1.4	51.2 / 0.7	24,1%	3,7%
Kidney 8 (right)	66.9 / 1.0	66.3 / 0.7	58.0 / 0.5	13,3%	0,9%
Kidney 8 (left)	70.4 / 0.8	69.2 / 0.7	58.3 / 0.8	17,2%	1,7%
Large Intestine 4 (right)	65.4 / 0.7	65.1 / 0.7	52.2 / 0.9	20,2%	0,5%
Large Intestine 4 (left)	70.7 / 1.1	70.3 / 1.3	60.3 / 0.8	14,7%	0,6%
Large Intestine 11 (right)	64.7 / 0.9	65.1 / 1.0	57.5 / 0.8	11,1%	-0,6%
Large Intestine 11 (left)	62.3 / 0.8	61.8 / 0.8	57.8 / 0.1	7,2%	0,8%
Stomach 3 (right)	69.9 / 0.7	66.1 / 0.8	52.4 / 1.1	25,0%	5,4%
Stomach 3 (left)	66.6 / 0.2	68.5 / 0.6	59.3 / 1.8	11,0%	-2,9%
Anxiety					
Conception Vessel 12	66.0 / 0.4	65.1/0.2	50.3 / 1.4	23,8%	100,0%
Liver 3 (right)	63.0 / 0.8	64.9 / 0.5	65.7 / 1.3	-4,3%	-3,0%
GV 16	64.7 / 0.5	65.8 / 0.7	50.8 / 0.5	21,5%	-1,7%
Eye Disorders					
Gbl 1 (right)	60.2 / 0.7	56.5 / 1.2	50.0 / 1.3	16,9%	6,1%
Gbl 1 (left)	58.1 / 0.8	57.7 / 0.8	55.2 / 1.1	5,0%	0,7%
OR11 (left)	58.8 / 0.4	71.5 / 0.5	50.2 / 0.5	14,6%	-21,6%
OR10 (right)	65.4 / 0.8	56.9 / 1.4	53.5 / 0.5	18,2%	13,0%
OR 6 (right)	59.7 / 0.6	58.9 / 0.2	57.0 / 1.1	4,5%	1,3%
OR 9 (left)	60.5 / 0.7	59.3 / 1.0	58.2 / 0.8	3,8%	2,0%
CX1 -specific for blurred vision (right)	64.6 / 1.2	59.3/0.4	56.4 / 0.4	12,7%	8,2%
CX1 -specific for blurred vision (left)	62.9 / 1.2	56.2/0.7	53.4 / 0.6	15,1%	10,7%
GB20 -specific for dull vision and eye fatigue (right)	68.0 / 1.0	58.6/0.3	54.3 / 0.2	20,1%	13,8%
GB20 -specific for dull vision and eye fatigue (left)	72.6 / 0.9	59.2/0.7	56.6 / 1.3	22,0%	18,5%
CX6 -specific for Glaucoma (right)	73.8 / 0.6	58.2/0.6	53.2/0.1	27,9%	21,1%

CX6 -specific for Glaucoma (left)	76.1 / 1.3	59.8/0.4	54.1/0.3	28,9%	21,4%
GV 23-2	62.3 / 1.0	63.1 / 0.2	55.7 / 0.7	10,6%	-1,3%
Stress					
H 6a (right)	59.2 / 0.8	58.7 / 1.0	59.1 / 0.7	0,2%	0,8%
H 6a (left)	62.2 / 0.9	58.1 / 1.1	53.9 / 1.2	13,3%	6,6%
Gbl 19a (left)	65.3 / 1.4	66.5 / 0.7	64.5 / 0.9	1,2%	-1,8%
Gbl 19a (right)	65.0 / 0.8	65.1 / 0.6	52.5 / 0.6	19,2%	-0,2%
St36 (right)	60.0 / 0.4	61.7 / 0.6	54.1 / 0.8	9,8%	-2,8%
St36 (left)	60.3 / 0.8	60.7 / 1.2	62.6 / 1.3	-3,8%	-0,7%
UB34 (right)	58.9 / 0.8	58.1 / 1.3	59.3 / 0.9	-0,7%	1,4%
UB34 (left)	62.7 / 1.3	57.0 / 0.6	57.0 / 1.1	9,1%	9,1%
Migraine					
GV 23-2 -eye pain/ migraine	62.3 / 1.0	63.1 / 0.2	55.7 / 0.7	10,6%	-1,3%
Gbl-1 (right) eye disorders/ migraine	60.2 / 0.7	56.5 / 1.2	50.0 / 1.3	16,9%	6,1%
Gbl-1(left) eye disorders/migraine	58.1 / 0.8	57.7 / 0.8	55.2 / 1.1	5,0%	0,7%
GV 16 anxiety/migraine	64.7 / 0.5	65.8 / 0.7	50.8 / 0.5	21,5%	-1,7%
Name: #27					
		Set 27-1	Set 27-2		
Points Tested:	Peak / Drop	Peak / Drop	Peak / Drop	% of Change	% of Change
Mental Focus		Baseline	Active	Placebo	
Hypothalamus (right)	81.5/1.0	79.2/1.5	65.8/1.6	19,3%	2,8%
Hypothalamus (left)	71.1/1.3	69.0/0.8	55.2/1.3	22,4%	3,0%
Small Intestine 5 (right)	71.9/0.1	64.4/0.7	52.2/1.3	27,4%	10,4%
Small Intestine 5 (left)	69.1/1.0	64.9/0.7	55.0/1.4	20,4%	6,1%
Kidney 8 (right)	59.5/1.4	59.2/0.9	56.5/0.8	5,0%	0,5%
Kidney 8 (left)	57.9/0.5	59.2/0.9	64.4/0.3	-11,2%	-2,2%
Large Intestine 4 (right)	71.8/0.3	57.0/1.2	67.4/0.9	6,1%	20,6%
Large Intestine 4 (left)	65.8/1.1	58.0/0.9	59.7/1.5	9,3%	11,9%
Large Intestine 11 (right)	73.8/0.4	59.9/1.5	63.7/0.6	13,7%	18,8%
Large Intestine 11 (left)	77.9/0.9	59.0/1.7	58.2/1.1	25,3%	24,3%
Stomach 3 (right)	71.7/0.5	61.1/1.5	56.9/0.4	20,6%	14,8%
Stomach 3 (left)	72.9/0.1	66.6/1.6	60.6/1.0	16,9%	8,6%
Anxiety					
Conception Vessel 12					
Liver 3 (right)	73.2/1.1	55.2/1.8	64.5/1.4	11,9%	24,6%
GV 16	72.8/0.6	56.1/0.7	64.2/1.4	11,8%	22,9%

Eye Disorders					
Gbl 1 (right)	69.9/0.6	54.3/1.6	55.5/1.2	20,6%	22,3%
Gbl 1 (left)	72.0/0.8	64.9/1.5	53.7/1.3	25,4%	9,9%
OR11 (left)	74.8/1.5	56.7/0.8	59.2/1.4	20,9%	24,2%
OR10 (right)	70.9/1.1	66.4/1.0	54.3/0.9	23,4%	6,3%
OR 6 (right)	71.5/0.6	53.7/2.0	78.4/0.8	-9,7%	24,9%
OR 9 (left)	68.8/0.7	68.3/3.2	55.7/0.2	19,0%	0,7%
CX1 -specific for blurred vision (right)					
CX1 -specific for blurred vision (left)					
GB20 -specific for dull vision and eye fatigue (right)					
GB20 -specific for dull vision and eye fatigue (left)					
CX6 -specific for Glaucoma (right)					
CX6 -specific for Glaucoma (left)					
GV 23-2	64.6/0.2	70.8/1.8	62.9/2.4	2,6%	-9,6%
Stress					
H 6a (right)	63.8/2.7	57.7/1.9	49.5/1.1	22,4%	9,6%
H 6a (left)	64.9/1.1	66.5/2.3	50.3/1.5	22,5%	-2,5%
Gbl 19a (left)	65.9/0.5	60.9/2.5	65.6/2.2	0,5%	7,6%
Gbl 19a (right)	63.6/0.5	68.3/1.4	57.8/1.7	9,1%	-7,4%
St36 (right)	70.3/0.2	56.1/0.4	63.6/1.9	9,5%	20,2%
St36 (left)	69.6/1.0	55.7/1.4	52.2/1.7	25,0%	20,0%
UB34 (right)	72.5/1.0	60.2/1.0	65.2/1.5	10,1%	17,0%
UB34 (left)	71.7/0.5	55.7/1.4	49.8/1.3	30,5%	22,3%
Migraine					
GV 23-2 -eye pain/ migraine	64.6/0.2	70.8/1.8	62.9/2.4	2,6%	-9,6%
Gbl-1 (right) eye disorders/ migraine	69.9/0.6	54.3/1.6	55.5/1.2	20,6%	22,3%
Gbl-1(left) eye disorders/migraine	72.0/0.8	64.9/1.5	53.7/1.3	25,4%	9,9%
GV 16 anxiety/migraine	72.8/0.6	56.1/0.7	64.2/1.4	11,8%	22,9%
Name: #28 (Steve)					
		Set 28-1	Set 28-2		
Points Tested:	Peak / Drop	Peak / Drop	Peak / Drop	% of Change	% of Change
Mental Focus	Baseline	Active	Placebo		
Hypothalamus (right)	58.5 / 1.1	53.1 / 0.3	60.6 / 1.0	9,2%	-3,6%
Hypothalamus (left)	55.9 / 1.0	57.2 / 1.0	58.6 / 2.0	-2,3%	-4,8%
Small Intestine 5 (right)	66.1 / 2.3	58.1 / 1.3	63.6 / 0.7	12,1%	3,8%
Small Intestine 5 (left)	58.4 / 1.3	54.7 / 0.5	59.1 / 1.6	6,3%	-1,2%

Kidney 8 (right)	60.7 / 1.8	55.7 / 1.6	62.6 / 0.8	8,2%	-3,1%
Kidney 8 (left)	57.8 / 1.5	56.0 / 1.0	59.1 / 0.8	3,1%	-2,2%
Large Intestine 4 (right)	57.5 / 0.9	56.5 / 0.8	57.0 / 0.7	1,7%	0,9%
Large Intestine 4 (left)	62.7 / 1.3	52.6 / 1.0	60.1 / 0.4	16,1%	4,1%
Large Intestine 11 (right)	60.2 / 0.7	50.4 / 1.0	60.4 / 0.6	16,3%	-0,3%
Large Intestine 11 (left)	55.1 / 0.9	50.8 / 0.6	58.5 / 1.3	7,8%	-6,2%
Stomach 3 (right)	63.9 / 0.9	51.5 / 0.0	61.0 / 1.3	19,4%	4,5%
Stomach 3 (left)	64.1 / 1.5	50.1 / 0.9	61.8 / 1.0	21,8%	3,6%
Anxiety					
Conception Vessel 12	56.9 / 0.7	49.8 / 1.2	57.5 / 0.9	12,5%	-1,1%
Liver 3 (right)	65.6 / 1.4	50.8 / 0.8	63.8 / 0.5	22,6%	2,7%
GV 16	59.2 / 0.8	50.9 / 0.3	58.7 / 1.2	14,0%	0,8%
Eye Disorders					
Gbl 1 (right)	60.4 / 0.7	52.1/0.6	59.3 / 1.1	13,7%	1,8%
Gbl 1 (left)	64.6 / 0.7	51.3 / 0.7	60.8 / 0.4	20,6%	5,9%
OR11 (left)	55.0 / 1.1	52.0 / 1.4	59.9 / 1.0	5,5%	-8,9%
OR10 (right)	59.0 / 1.3	53.1 / 0.4	56.8 / 0.7	10,0%	3,7%
OR 6 (right)	55.3 / 2.7	50.3 / 0.9	55.2 / 0.9	9,0%	0,2%
OR 9 (left)	57.5 / 2.9	49.9 / 0.1	54.8 / 0.0	13,2%	4,7%
CX1 -specific for blurred vision (right)	60.1 / 2.2	49.8 / 0.4	59.3/1.3	17,1%	1,3%
CX1 -specific for blurred vision (left)	61.5 / 1.8	50.2 / 1.0	59.7/1.2	18,4%	2,9%
GB20 -specific for dull vision and eye fatigue (right)	55.5 / 1.2	51.1 / 0.6	56.3 / 0.9	7,9%	-1,4%
GB20 -specific for dull vision and eye fatigue (left)	58.5 / 1.0	49.5 / 0.8	57.6 / 1.3	15,4%	1,5%
CX6 -specific for Glaucoma (right)	62.5 / 1.1	49.4 / 0.6	60.4 / 0.9	21,0%	3,4%
CX6 -specific for Glaucoma (left)	57.1 / 1.6	53.0 / 1.2	55.4 / 1.8	7,2%	3,0%
GV 23-2	60.6 / 0.6	50.0 / 1.0	58.2 / 1.0	17,5%	4,0%
Stress					
H 6a (right)	52.5 / 0.7	51.9 / 0.2	54.7 / 0.6	1,1%	-4,2%
H 6a (left)	55.5 / 0.7	52.0 / 0.5	55.7 / 1.0	6,3%	-0,4%
Gbl 19a (left)	62.6 / 1.0	50.6 / 0.6	63.1 / 1.4	19,2%	-0,8%
Gbl 19a (right)	63.0 / 1.4	50.2/0.3	61.7 / 0.6	20,3%	2,1%
St36 (right)	50.5 / 1.1	4.9 / 0.0	52.8 / 0.8	90,3%	-4,6%
St36 (left)	53.4 / 1.7	50.9 / 1.3	53.0 / 0.5	4,7%	0,7%
UB34 (right)	53.3 / 0.9	49.9 / 1.0	55.2 / 1.1	6,4%	-3,6%
UB34 (left)	55.0 / 0.4	51.6 / 1.0	53.4 / 0.5	6,2%	2,9%
Migraine					
GV 23-2 -eye pain/ migraine	60.6 / 0.6	50.0 / 1.0	58.2 / 1.0	17,5%	4,0%

Gbl-1 (right) eye disorders/ migraine	60.4 / 0.7	52.1/0.6	59.3 / 1.1	13,7%	1,8%
Gbl-1(left) eye disorders/migraine	64.6 / 0.7	51.3 / 0.7	60.8 / 0.4	20,6%	5,9%
GV 16 anxiety/migraine	59.2 / 0.8	50.9 / 0.3	58.7 / 1.2	14,0%	0,8%
Name: #29 (Evan)					
		Set 29-1	Set 29-2		
Points Tested:	Peak / Drop	Peak / Drop	Peak / Drop	% of Change	% of Change
Mental Focus	Baseline	Placebo	Active		
Hypothalamus (right)	52.8 / 1.3 51.4 / 0.9	54.3 / 1.7	54.2 / 1.0	-2,7%	-2,8%
Hypothalamus (left)	51.7 / 0.8	51.2 / 1.3	49.7 / 0.5	3,9%	1,0%
Small Intestine 5 (right)	59.9 / 1.0	58.1 / 1.4	54.4 / 1.6	9,2%	3,0%
Small Intestine 5 (left)	58.2 / 1.3	57.4 / 0.8	49.5 / 0.6	14,9%	1,4%
Kidney 8 (right)	61.6 / 0.6	58.5 / 1.2	50.6 / 0.8	17,9%	5,0%
Kidney 8 (left)	61.7 / 1.4	65.1 / 1.6	53.6 / 0.7	13,1%	-5,5%
Large Intestine 4 (right)	61.1 / 1.0	60.7 / 0.9	49.9 / 0.8	18,3%	0,7%
Large Intestine 4 (left)	51.4 / 0.4	54.2 / 0.9	49.9 / 0.8	2,9%	-5,4%
Large Intestine 11 (right)	49.9 / 0.9	50.8 / 0.3	52.6 / 1.0	-5,4%	-1,8%
Large Intestine 11 (left)	64.5 / 2.2	63.4 / 1.4	50.0 / 1.2	22,5%	1,7%
Stomach 3 (right)	57.9 / 1.1	55.8 / 0.8	50.5 / 1.0	12,8%	3,6%
Stomach 3 (left)	60.4 / 1.2	56.3 / 1.1	49.9 / 0.7	17,4%	6,8%
Anxiety					
Conception Vessel 12	63.7 / 0.4	62.9 / 1.6	55.1 / 1.1	13,5%	1,3%
Liver 3 (right)	57.2 / 0.8	56.9 / 0.7	50.9 / 1.0	11,0%	0,5%
GV 16	62.1 / 0.6	60.3 / 1.6	51.2 / 1.1	17,6%	2,9%
Eye Disorders					
Gbl 1 (right)	60.9 / 0.5	58.6 / 1.1	49.9 / 1.1	18,1%	3,8%
Gbl 1 (left)	59.6 / 1.3	60.7 / 0.5	51.1 / 1.1	14,3%	-1,8%
OR11 (left)	58.7 / 1.2	60.3 / 0.8	50.6 / 1.2	13,8%	-2,7%
OR10 (right)	63.5 / 0.7	63.7 / 0.6	51.0 / 0.9	19,7%	-0,3%
OR 6 (right)	54.6 / 0.4	57.1 / 1.3	49.2 / 0.5	9,9%	-4,6%
OR 9 (left)	57.2 / 0.4	54.2 / 1.6	54.2 / 1.4	5,2%	5,2%
CX1 -specific for blurred vision (right)	62.2 / 1.8	58.1/0.3	53.2/1.1	14,5%	6,6%
CX1 -specific for blurred vision (left)	54.3 / 0.6	54.0/0.2	51.1/0.7	5,9%	0,6%
GB20 -specific for dull vision and eye fatigue (right)	66.4 / 1.8	55.4 / 0.7	50.0 / 0.5	24,7%	16,6%
GB20 -specific for dull vision and eye fatigue (left)	55.1 / 1.1	53.6 / 1.0	50.9 / 1.1	7,6%	2,7%
CX6 -specific for Glaucoma (right)	63.6 / 0.8	63.3 / 1.3	50.1 / 0.7	21,2%	0,5%

CX6 -specific for Glaucoma (left)	54.6 / 1.5	54.4 / 1.2	52.9 / 1.2	3,1%	0,4%
GV 23-2	59.6 / 0.7	56.3 / 0.7	49.6 / 0.7	16,8%	5,5%
Stress					
H 6a (right)	62.2 / 0.6	65.6 / 2.2	50.9 / 0.9	18,2%	-5,5%
H 6a (left)	58.0 / 0.9	59.7 / 0.6	49.8 / 0.9	14,1%	-2,9%
Gbl 19a (left)	61.1 / 1.3	58.8 / 0.6	50.4 / 1.3	17,5%	3,8%
Gbl 19a (right)	60.9 / 1.6	60.6 / 1.5	53.7 / 1.9	11,8%	0,5%
St36 (right)	54.3 / 0.8	56.7 / 1.0	50.1 / 1.0	7,7%	-4,4%
St36 (left)	57.4 / 0.5	57.8 / 0.8	49.5 / 0.9	13,8%	-0,7%
UB34 (right)	54.8 / 1.0	58.6 / 1.2	50.1 / 0.5	8,6%	-6,9%
UB34 (left)	54.9 / 0.9	55.6 / 0.7	53.7 / 0.9	2,2%	-1,3%
Migraine					
GV 23-2 -eye pain/ migraine	59.6 / 0.7	56.3 / 0.7	49.6 / 0.7	16,8%	5,5%
Gbl-1 (right) eye disorders/ migraine	59.6 / 1.3	60.7 / 0.5	51.1 / 1.1	14,3%	-1,8%
Gbl-1(left) eye disorders/migraine	58.7 / 1.2	60.3 / 0.8	50.6 / 1.2	13,8%	-2,7%
GV 16 anxiety/migraine	62.1 / 0.6	60.3 / 1.6	51.2 / 1.1	17,6%	2,9%
Name: #30 Female					
		Set 30-1	Set 30-2		
Points Tested:	Peak / Drop	Peak / Drop	Peak / Drop	% of Change	% of Change
Mental Focus	Baseline	Placebo	Active		
Hypothalamus (right)	63.4/0.5	71.3/1.7	77.7/0.8	-22,6%	-12,5%
Hypothalamus (left)	63.2/0.9	62.4/1.0	68.3/1.4	-8,1%	1,3%
Small Intestine 5 (right)	50.3/1.3	61.3/0.6	66.6/1.7	-32,4%	-21,9%
Small Intestine 5 (left)	64.1/1.3	65.8/0.9	57.9/2.6	9,7%	-2,7%
Kidney 8 (right)	72.4/1.0	52.5/1.1	51.8/1.3	28,5%	27,5%
Kidney 8 (left)	64.2/2.0	62.1/0.8	66.5/0.5	-3,6%	3,3%
Large Intestine 4 (right)	63.9/1.1	64.5/0.9	50.8/0.7	20,5%	-0,9%
Large Intestine 4 (left)	64.2/0.9	60.9/1.2	64.3/2.0	-0,2%	5,1%
Large Intestine 11 (right)	66.7/1.0	59.6/1.1	51.9/1.2	22,2%	10,6%
Large Intestine 11 (left)	71.8/1.0	62.9/0.7	51.0/1.0	29,0%	12,4%
Stomach 3 (right)	70.7/0.7	63.3/0.5	60.8/0.8	14,0%	10,5%
Stomach 3 (left)	58.8/1.4	61.8/1.0	60.7/0.6	-3,2%	-5,1%
Anxiety					
Conception Vessel 12	55.5/0.8	61.1/1.3	53.4/1.1	-10,1%	3,8%
Liver 3 (right)	71.1/0.7	60.2/1.1	58.9/1.1	17,2%	15,3%
GV 16	68.5/1/3	66.6/0.9	63.4/0.9	7,4%	2,8%

Eye Disorders					
Gbl 1 (right)	72.0/0.8	62.7/1.6	53.6/1.1	25,6%	12,9%
Gbl 1 (left)	68.3/1.1	62.8/0.8	56.6/0.8	17,1%	8,1%
OR11 (left)	73.7/0.9	61.1/0.9	58.6/1.4	20,5%	17,1%
OR10 (right)	70.5/1.5	60.0/0.8	61.0/0.9	13,5%	14,9%
OR 6 (right)	69.8/0.7	65.7/0.3	63.9/1.1	8,5%	5,9%
OR 9 (left)	75.2/1.3	55.3/1.7	61.5/0.3	18,5%	26,8%
CX1 -specific for blurred vision (right)	60.1/0.5	62.2/3.6	49.6/0.5	-3,5%	17,5%
CX1 -specific for blurred vision (left)	58.4/0.6	51.8/1.3	49.6/0.8	11,3%	15,1%
GB20 -specific for dull vision and eye fatigue (right)	61.1/0.7	54.3/0.5	49.3/0.4	11,1%	19,3%
GB20 -specific for dull vision and eye fatigue (left)	54.1/0.6	51.3/0.7	50.4/0.6	5,2%	6,8%
CX6 -specific for Glaucoma (right)	56.3/0.6	55.3/1.3	50.1/1.0	1,8%	11,0%
CX6 -specific for Glaucoma (left)	57.3/0.6	57.6/1.0	51.2/0.6	-0,5%	10,6%
GV 23-2	67.8/0.4	57.8/1.0	60.04/0.1	11,4%	14,7%
Stress					
H 6a (right)	69.6/1.0	65.3/1.3	59.4/1.8	14,7%	6,2%
H 6a (left)	70.1/1.2	62.7/0.7	63.2/0.8	9,8%	10,6%
Gbl 19a (left)	71.9/1.1	62.5/1.4	53.5/1.1	25,6%	13,1%
Gbl 19a (right)	74.0/0.8	50.4/0.6	63.8/0.7	13,8%	31,9%
St36 (right)	71.6/1.3	57.2/0.8	61.6/1.6	14,0%	20,1%
St36 (left)	67.9/0.4	61.8/0.7	61.0/1.8	10,2%	9,0%
UB34 (right)	75.4/1.0	60.9/0.5	63.8/1.2	15,4%	19,2%
UB34 (left)	74.3/1.1	58.1/0.9	62.5/1.5	15,9%	21,8%
Migraine					
GV 23-2 -eye pain/ migraine	67.8/0.4	57.8/1.0	60.4/0.1	11,4%	14,7%
Gbl-1 (right) eye disorders/ migraine	72.0/0.8	62.7/1.6	53.6/1.1	25,6%	12,9%
Gbl-1(left) eye disorders/migraine	68.3/1.1	62.8/0.8	56.6/0.8	17,1%	8,1%
GV 16 anxiety/migraine	68.5/1/3	66.6/0.9	63.4/0.9	7,4%	2,8%













































































